



(11) **EP 1 576 166 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**15.10.2014 Bulletin 2014/42**

(51) Int Cl.:  
**C12N 15/82** (2006.01) **C12P 7/64** (2006.01)  
**C12N 9/02** (2006.01) **C12N 9/10** (2006.01)

(21) Application number: **03813566.1**

(86) International application number:  
**PCT/EP2003/014054**

(22) Date of filing: **11.12.2003**

(87) International publication number:  
**WO 2004/057001 (08.07.2004 Gazette 2004/28)**

(54) **NOVEL METHOD FOR THE PRODUCTION OF POLYUNSATURATED FATTY ACIDS**  
**VERFAHREN ZUR HERSTELLUNG VON MEHRFACH UNGESÄTTIGTEN FETTSÄUREN**  
**NOUVEAU PROCÉDE DE PRODUCTION D'ACIDES GRAS POLYINSATURÉS**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **19.12.2002 GB 0229578**  
**21.07.2003 GB 0316989**

(43) Date of publication of application:  
**21.09.2005 Bulletin 2005/38**

(73) Proprietor: **UNIVERSITY OF BRISTOL**  
**Bristol BS8 1TH (GB)**

(72) Inventors:  
• **NAPIER, Johnathan, A.**  
**Harpenden, Hertfordshire AL5 2JH (GB)**  
• **SAYANOVA, Olga**  
**(GB)**  
• **LAZARUS, Colin, M.**  
**Montpelier, Bristol BS6 5QG (GB)**  
• **QI, Baoxiu**  
**Norfolk Crescent, Somerset BAI 2BG (GB)**

- **HEINZ, Ernst**  
**22609 Hamburg (DE)**
- **ZANK, Thorsten**  
**68165 Mannheim (DE)**
- **ZÄHRINGER, Ulrich**  
**22926 Ahrensburg (DE)**

(74) Representative: **Pressler, Uwe**  
**BASF SE**  
**Global Intellectual Property**  
**GVX - C6**  
**67056 Ludwigshafen (DE)**

(56) References cited:  
**WO-A-00/34439** **WO-A-02/057464**  
**WO-A-02/077213** **US-A1- 2002 138 874**  
**US-B1- 7 256 033**

- **WALLIS & BROWSE: "The delta-8-desaturase of Euglena gracilis: An alternate pathway for synthesis of 20-carbon polyunsaturated fatty acis", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 365, 1999, pages 307-316,**

**EP 1 576 166 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

**[0001]** The present invention relates to an improved process for the specific production of poly-unsaturated  $\omega$ -3 and  $\omega$ -6 fatty acids and a process for the production of triglycerides having an increased content of unsaturated fatty acids, in particular  $\omega$ -3 and  $\omega$ -6 fatty acids having at least two double bonds and a 20 or 22 carbon atom chain length. The invention relates to the production of a transgenic oil producing a plant, having an increased content of fatty acids, oils or lipids containing  $C_{20}$ - or  $C_{22}$ - fatty acids with a  $\Delta$ 5, 7, 8, 10 double bond, respectively due to the expression of a  $\Delta$ 8-desaturase and a  $\Delta$ 9-elongase from organisms such as plants preferably Algae like *Isochrysis galbana* or *Euglena gracilis*. In addition the invention relates to a process for the production of poly unsaturated fatty acids such as Eicosapentaenoic, Arachidonic, Docosapentaenoic or Docosahexaenoic acid through the co-expression of a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and a  $\Delta$ -5 desaturase in organisms such as plants.

**[0002]** The invention additionally relates to the use of specific nucleic acid sequences encoding for the aforementioned proteins with  $\Delta$ -8-desaturase-,  $\Delta$ -9-elongase- or  $\Delta$ -5-desaturase-activity, nucleic acid constructs, vectors and organisms containing said nucleic acid sequences. Also disclosed are unsaturated fatty acids and triglycerides having an increased content of at least 1 % by weight of unsaturated fatty acids and use thereof.

**[0003]** Fatty acids and triglycerides have numerous applications in the food industry, animal nutrition, cosmetics and in the drug sector. Depending on whether they are free saturated or unsaturated fatty acids or triglycerides with an increased content of saturated or unsaturated fatty acids, they are suitable for the most varied applications; thus, for example, polyunsaturated fatty acids (= PUFAs) are added to infant formula to increase its nutritional value. The various fatty acids and triglycerides are mainly obtained from microorganisms such as *Mortierella* or from oil-producing plants such as soybean, oilseed rape, sunflower and others, where they are usually obtained in the form of their triacylglycerides. Alternatively, they are obtained advantageously from animals, such as fish. The free fatty acids are prepared advantageously by hydrolysis.

**[0004]** Whether oils with unsaturated or with saturated fatty acids are preferred depends on the intended purpose; thus, for example, lipids with unsaturated fatty acids, specifically polyunsaturated fatty acids, are preferred in human nutrition since they have a positive effect on the cholesterol level in the blood and thus on the possibility of heart disease. They are used in a variety of dietetic foodstuffs or medicaments. In addition PUFAs are commonly used in food, feed and in the cosmetic industry. Poly unsaturated  $\omega$ -3-and/or  $\omega$ -6-fatty acids are an important part of animal feed and human food. Because of the common composition of human food poly unsaturated  $\omega$ -3-fatty acids, which are an essential component of fish oil, should be added to the food to increase the nutritional value of the food; thus, for example, poly unsaturated fatty acids such as Docosahexaenoic acid (= DHA,  $C_{22:6}^{\Delta 4,7,10,13,16,19}$ ) or Eicosapentaenoic acid (= EPA,  $C_{20:5}^{\Delta 5,8,11,14,17}$ ) are added as mentioned above to infant formula to increase its nutritional value. Whereas DHA has a positive effect of the brain development of babies. The addition of poly unsaturated  $\omega$ -3-fatty acids is preferred as the addition of poly unsaturated  $\omega$ -6-fatty acids like Arachidonic acid (= ARA,  $C_{20:4}^{\Delta 5,8,11,14}$ ) to common food have an undesired effect for example on rheumatic diseases such as rheumatoid arthritis. Poly unsaturated  $\omega$ -3- and  $\omega$ -6-fatty acids are precursor of a family of paracrine hormones called eicosanoids such as prostaglandins which are products of the metabolism of Dihomo- $\gamma$ -linoleic acid, ARA or EPA. Eicosanoids are involved in the regulation of lipolysis, the initiation of inflammatory responses, the regulation of blood circulation and pressure and other central functions of the body. Eicosanoids comprise prostaglandins, leukotrienes, thromboxanes, and prostacyclins.  $\omega$ -3-fatty acids seem to prevent atherosclerosis and cardiovascular diseases primarily by regulating the levels of different eicosanoids. Other Eicosanoids are the thromboxanes and leukotrienes which are products of the metabolism of ARA or EPA.

**[0005]** Principally microorganisms such as *Mortierella* or oil producing plants such as soybean, rapeseed or sunflower or algae such as *Cryptocodium* or *Phaeodactylum* are a common source for oils containing PUFAs, where they are usually obtained in the form of their triacyl glycerides. Alternatively, they are obtained advantageously from animals, such as fish. The free fatty acids are prepared advantageously by hydrolysis with a strong base such as potassium or sodium hydroxide. Higher poly unsaturated fatty acids such as DHA, EPA, ARA, Dihomo- $\gamma$ -linoleic acid ( $C_{20:3}^{\Delta 8,11,14}$ ) or Docosapentaenoic acid (= DPA,  $C_{22:5}^{\Delta 7,10,13,16,19}$ ) are not produced by oil producing plants such as soybean, rapeseed, safflower or sunflower. A natural sources for said fatty acids are fish for example herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, pike-perch or tuna or algae.

**[0006]** On account of their positive properties there has been no shortage of attempts in the past to make available genes which participate in the synthesis of fatty acids or triglycerides for the production of oils in various organisms having a modified content of unsaturated fatty acids. Thus, in WO 91/13972 and its US equivalent a  $\Delta$ -9-desaturase is described. In WO 93/11245 a  $\Delta$ -15-desaturase and in WO 94/11516 a  $\Delta$ -12-desaturase is claimed. WO 00/34439 discloses a  $\Delta$ -5- and a  $\Delta$ -8-desaturase. Other desaturases are described, for example, in EP-A-0 550162, WO 94/18337, WO 97/30582, WO 97/21340, WO 95/18222, EP-A-0 794 250, Stucky et al., J. Biol. Chem., 265,1990: 20144-20149, Wada et al., Nature 347, 1990: 200-203 or Huang et al., Lipids 34, 1999: 649-659. To date, however, the various desaturases have been only inadequately characterized biochemically since the enzymes in the form of membrane-bound proteins are isolable and characterizable only with very great difficulty (McKeon et al., Methods in Enzymol. 71,

1981: 12141-12147, Wang et al., Plant Physiol. Biochem., 26, 1988: 777-792). Generally, membrane-bound desaturases are characterized by introduction into a suitable organism which is then investigated for enzyme activity by means of analysis of starting materials and products. Δ-6-Desaturases are described in WO 93/06712, US 5,614,393, US 5,614,393, WO 96/21022, WO0021557 and WO 99/27111 and their application to production in transgenic organisms is also described, e.g. in WO 9846763, WO 9846764 and WO 9846765. At the same time the expression of various fatty acid biosynthesis genes, as in WO 9964616 or WO 9846776, and the formation of poly-unsaturated fatty acids is also described and claimed.


**[0007]** From US2002/0138874 A1 the identification and uses of several genes involved in the elongation of monounsaturated fatty acids, especially a functionally active elongase, which utilize a monounsaturated fatty acid as a substrate is known. WO 02/077213 A3 describes an elongase gene encoding a polypeptide which elongates α-linolenic acid by at least two carbon atoms whereas γ-linolenic acid is not elongated.

**[0008]** With regard to the effectiveness of the expression of desaturases and elongases as described to date only low contents of poly-unsaturated fatty acids/lipids, such as by way of example eicosapentaenoic or arachidonic acid, have been achieved. Therefore, an alternative and more effective pathway with higher product yield is desirable.

**[0009]** Accordingly, there is still a great demand for new and more suitable genes which encode enzymes which participate in the biosynthesis of unsaturated fatty acids and make it possible to produce certain fatty acids specifically on an industrial scale without unwanted byproducts forming. In the selection of genes for biosynthesis two characteristics above all are particularly important. On the one hand, there is as ever a need for improved processes for obtaining the highest possible contents of polyunsaturated fatty acids.

**[0010]** Accordingly, it is an object of the present invention to provide further genes of desaturase and elongase enzymes for the synthesis of polyunsaturated fatty acids in organisms preferably in microorganisms and plants and to use them in a commercial process for the production of poly unsaturated fatty acids. Said process should increase PUFA content in organisms as much as possible preferably in seeds of an oil producing plant.


**[0011]** We have found that this object is achieved by a process for the production of compounds of the following general formula



in transgenic oil producing plant with a content of at least 1 % by weight of said compounds referred to the total lipid content of said oil producing plant which comprises the following steps:

- a) introduction of at least one nucleic acid sequence in a transgenic oil producing plant, which encodes a Δ-9-elongase having a nucleic acid sequence depicted in SEQ ID NO:3, and
  - b) introduction of at least one second nucleic acid sequence which encodes a Δ-8-desaturase having a nucleic acid sequence depicted in SEQ ID NO:1, and
  - c) if necessary introduction of at least a third nucleic acid sequence, which encodes a Δ-5-desaturase having a nucleic acid sequence depicted in SEQ ID NO:5, 7 or 9, and
  - d) cultivating and harvesting of said oil producing plant; and
- where the variables and substituents in formula I have the following meanings:

R<sup>1</sup> = hydroxyl-, Coenzyme A-(Thioester), phosphatidylcholine-, phosphatidylethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, sphingolipid-, glycosphingolipid- or a residue of the general formula II:




where the substituents in formula II have the following meanings:

$\text{R}^2 =$  hydrogen-, phosphatidylcholine-, phosphatidylethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, shingolipid-, glycoshingolipid-, glycoshingolipid- or saturated or unsaturated  $\text{C}_2$ - $\text{C}_{24}$ -alkylcarbonyl-,


$\text{R}^3 =$  hydrogen-, saturated or unsaturated  $\text{C}_2$ - $\text{C}_{24}$ -alkylcarbonyl-, or

$\text{R}^2$  and  $\text{R}^3$  independent of each other a residue of the formula Ia:



$n =$  3,4 or 6,  $m =$  3, 4 or 5 and  $p =$  0 or 3, preferably  $n =$  3,  $m =$  4 or 5 and  $p =$  0 or 3.

$\text{R}^1$  indicates in the formula I hydroxyl-, Acetyl-Coenzyme A-, phosphatidylcholine-, phosphatidylethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, sphingolipid-, glycoshingolipid- or a residue of the general formula II



**[0012]** The abovementioned residues for  $\text{R}^1$  are always coupled to compounds of the general formula I in the form of their ester or thioester.

**[0013]**  $\text{R}^2$  indicates in structures of the general formula II hydrogen, phosphatidylcholine-, phosphatidylethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, shingolipid-, glycoshingolipid-, glycoshingolipid- or saturated or unsaturated  $\text{C}_2$ - $\text{C}_{24}$ -alkylcarbonyl-residues,


**[0014]** Alkyl radicals which may be mentioned are substituted or unsubstituted, saturated or unsaturated  $\text{C}_2$ - $\text{C}_{24}$ -alkylcarbonyl- chains such as ethylcarbonyl-, n-propylcarbonyl-, n-butylcarbonyl-, n-pentylcarbonyl-, n-hexylcarbonyl-, n-heptylcarbonyl-, n-octyl-carbonyl-, n-nonylcarbonyl-, n-decylcarbonyl-, n-undecylcarbonyl-, n-dodecylcarbonyl-, n-tridecylcarbonyl-, n-tetradecylcarbonyl-, n-pentadecylcarbonyl-, n-hexadecylcarbonyl-, n-heptadecylcarbonyl-, n-octadecylcarbonyl-, n-nonadecylcarbonyl-, n-eicosylcarbonyl-, n-docosanylcarbonyl- or n-tetracosanylcarbonyl-, that contain one or more double bonds. Saturated or unsaturated  $\text{C}_{10}$ - $\text{C}_{22}$ -Alkylcarbonylresidues such as n-decylcarbonyl-, n-undecylcarbonyl-, n-dodecylcarbonyl-, n-tridecylcarbonyl-, n-tetra-decylcarbonyl-, n-pentadecylcarbonyl-, n-hexadecylcarbonyl-, n-heptadecylcarbonyl-, n-octadecylcarbonyl-, n-nonadecylcarbonyl-, n-eicosylcarbonyl-, n-docosanyl-carbonyl- or n-tetracosanylcarbonyl- are preferred, which contain one ore more double bonds. In particular privileged are saturated or unsaturated  $\text{C}_{10}$ - $\text{C}_{22}$ -alkylcarbonyl-residue as  $\text{C}_{10}$ -alkylcarbonyl-,  $\text{C}_{11}$ -alkylcarbonyl-,  $\text{C}_{12}$ -alkylcarbonyl-,  $\text{C}_{13}$ -alkylcarbonyl-,  $\text{C}_{14}$ -alkylcarbonyl-,  $\text{C}_{16}$ -alkylcarbonyl-,  $\text{C}_{18}$ -alkylcarbonyl-,  $\text{C}_{20}$ -alkylcarbonyl-,  $\text{C}_{22}$ -alkylcarbonyl- or  $\text{C}_{24}$ -alkylcarbonyl-residue, that contain one ore more double bonds. In particular privileged are saturated or unsaturated  $\text{C}_{16}$ - $\text{C}_{22}$ -alkylcarbonylresidue as  $\text{C}_{16}$ -alkylcarbonyl-,  $\text{C}_{18}$ -alkylcarbonyl-,  $\text{C}_{20}$ -alkylcarbonyl- or  $\text{C}_{22}$ -alkylcarbonyl-residue, that contain one ore more double bonds. The residues contain in particular two, three, four or five double bonds. Particularly preferred are residues of 20 or 22 carbon atoms having up to five double bonds, preferably three, four or five

double bonds. All residues are derived from the mentioned corresponding fatty acids.

**[0015]** R<sup>3</sup> indicates in structures of the general formula II hydrogen, saturated or unsaturated C<sub>2</sub>-C<sub>24</sub>-alkylcarbonyl.

**[0016]** Substituted or unsubstituted, saturated or unsaturated C<sub>2</sub>-C<sub>24</sub>-alkylcarbonyl- residues are e. g. ethylcarbonyl-, n-propylcarbonyl-, n-butylcarbonyl-, n-pentylcarbonyl-, n-hexyl-carbonyl-, n-heptylcarbonyl-, n-octylcarbonyl-, n-nonyl-carbonyl-, n-decylcarbonyl-, n-undecylcarbonyl-, n-dodecylcarbonyl-, n-tridecylcarbonyl-, n-tetradecylcarbonyl-, n-pentadecylcarbonyl-, n-hexadecylcarbonyl-, n-heptadecylcarbonyl-, n-octadecylcarbonyl-, n-nonadecylcarbonyl-, n-eicosyl-carbonyl-, n-docosanylcarbonyl- or n-tetracosanylcarbonyl-, having one or more double bonds. Preferred are saturated or unsaturated C<sub>10</sub>-C<sub>24</sub>-alkylcarbonyl residues as n-decylcarbonyl-, n-undecylcarbonyl-, n-dodecylcarbonyl-, n-tridecyl-carbonyl-, n-tetradecylcarbonyl-, n-pentadecylcarbonyl-, n-hexadecylcarbonyl-, n-heptadecylcarbonyl-, n-octadecylcar-bonyl-, n-nonadecylcarbonyl-, n-eicosylcarbonyl-, n-docosanylcarbonyl- or n-tetracosanylcarbonyl-, with one or more double bonds. In particular saturated or unsaturated C<sub>10</sub>-C<sub>24</sub>-alkylcarbonyl residues as C<sub>10</sub>-alkylcarbonyl-, C<sub>11</sub>-alkyl-carbonyl-, C<sub>12</sub>-alkylcarbonyl-, C<sub>13</sub>-alkylcarbonyl-, C<sub>14</sub>-alkylcarbonyl-, C<sub>16</sub>-alkylcarbonyl-, C<sub>18</sub>-alkylcarbonyl-, C<sub>20</sub>-alkyl-carbonyl-, C<sub>22</sub>-alkylcarbonyl- or C<sub>24</sub>-alkylcarbonyl-residues with one or more double bonds. In particular preferred are saturated or unsaturated C<sub>16</sub>-C<sub>22</sub>-alkylcarbonylresidue as C<sub>16</sub>-alkylcarbonyl-, C<sub>18</sub>-alkylcarbonyl-, C<sub>20</sub>-alkylcarbonyl- or C<sub>22</sub>-alkylcarbonyl-residues, with multiple double bonds. C<sub>18</sub>-alkylcarbonyl-residues are particularly preferred, which contain one, two, three or four double bonds and C<sub>20</sub>-alkylcarbonyl-residues, with three, four or five double bonds. All residues are derived from the corresponding fatty acids.

**[0017]** R<sup>2</sup> and R<sup>3</sup> indicates in structures of the general formula II independent of each other a residue of the general formula Ia



whereas the variables in the formula I and Ia are defined as: n = 3, 4 or 6, m = 3, 4 or 5 and p = 0 or 3. In particular: n = 3, m = 4 or 5 and p = 0 or 3.

**[0018]** The abovementioned residues R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> can be substituted with hydroxyl- or epoxy-groups or might contain also triple bonds.

**[0019]** According to the invention the used nucleic acid sequences are isolated nucleic sequences coding for polypeptides having C<sub>20</sub>-Δ5- or Δ-8 desaturase or C<sub>18</sub>-Δ9-elongase activity.

**[0020]** The according to inventive process synthesized substances of formula I which contain as residue R<sup>1</sup> the residue of formula II contain preferentially a mixture of different residues R<sup>2</sup> or R<sup>3</sup>. The residues are derived from different fatty acid molecules as short chain fatty acids with 4 to 6 C-atoms, mid-chain fatty acids having 8 to 12 C-atoms and long-chain fatty acids with 14 to 24 C-atoms, whereas the long-chain fatty acids are preferred. Said long chain fatty acids are derived preferentially from C<sub>18</sub>- or C<sub>20</sub>-poly unsaturated fatty acids having advantageously between two and five double bonds. In addition the backbone of formula I is also derived from such a aforementioned fatty acid which advantageously is also different from R<sup>2</sup> and R<sup>3</sup>. That means compounds which are produced by the inventive process are in one aspect of the invention triglycerides of different substituted or unsubstituted, saturated or unsaturated fatty acid ester or thioesters.

**[0021]** Also disclosed are poly-unsaturated fatty acid esters (of the formula I) with 18, 20 or 22 fatty acid carbon atoms chain length with at least two double bonds, preferably three, four or five are particularly preferred.

**[0022]** In particular fatty acid molecules with three, four or five double bonds are preferred for the synthesis of eicosadienoic, eicosatrienoic, eicosatetraenoic (arachidonic-acid) and eicosapentaenoic acid (C<sub>20</sub>:2n-6, Δ11, 14; C<sub>20</sub>:3n-6, Δ8, 11, 14; C<sub>20</sub>:4n-6, Δ5, 8, 11, 14, C<sub>20</sub>:3n-3, Δ11, 14, 17; C<sub>20</sub>:4n-3, Δ8, 11, 14, 17; C<sub>20</sub>:5n-3, Δ5, 8, 11, 14, 17) in the inventive process, whereas arachidonic acid and eicosapentaenoic acid are most preferred. We have found that this object is advantageously achieved by the combined expression of three isolated nucleic acid sequences according to the invention which encode for polypeptides having the following activities: a polypeptides with C<sub>20</sub>-Δ-8-desaturase activity, a C<sub>18</sub>-Δ-9-elongase activity, and a C<sub>20</sub>-Δ-5 desaturase activity. This objective was achieved in particular by the co-expression of the isolated nucleic acid sequences according to the invention. C<sub>18</sub> fatty acids with a double bond in Δ-9-position are elongated by the Δ-9-elongase advantageously used in the inventive process. By the Δ-8-desaturase used in the process a double in Δ-8-position is introduced into C<sub>20</sub> fatty acids. In addition a double bond can be introduced into the fatty acid molecules in Δ-5-position by the Δ-5-desaturase.

**[0023]** The fatty acid ester of C<sub>18</sub>-, C<sub>20</sub>- and/or C<sub>22</sub>-poly unsaturated fatty acids synthesized in the inventive process advantageously in form of their triglycerides as ester or thioesters can be isolated from the producing organism for example from a microorganism or a plant in the form of an oil, lipid or lipid mixture for example as sphingolipids, phos-

phoglycerides, lipids, glycolipids such as glycosphingolipids, phospholipids such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol or diphosphatidylglycerol, or as monoacylglyceride, diacylglyceride or triacylglyceride or as other fatty acid esters such as acetyl-Coenzyme A thioester, which contain saturated or unsaturated fatty acids preferably poly unsaturated fatty acids with at least two preferably at least three double bonds in the fatty acid molecule. In addition to the in form of the aforementioned esters bound fatty acids also fatty acids bound in other compounds can be produced or also free fatty acids can be produced by the inventive process.

**[0024]** In general the transgenic oil producing plants used in the inventive process contain fatty acid esters or fatty acids in a distribution of nearly 80 to 90 % by weight of triacyl glycerides, 2 to 5 % by weight diacyl glycerides, 5 to 10 % by weight monoacyl glycerides, 1 to 5 % by weight free fatty acids and 2 to 8 % by weight phospholipids, whereas the total amount of the aforementioned compounds are all together a 100 % by weight.

**[0025]** In the inventive process(es) [the singular shall include the plural and vice versa] at least 1 % by weight, preferably at least 2, 3, 4 or 5 % by weight, more preferably at least 6, 7, 8, or 9 % by weight, most preferably 10, 20 or 30 % by weight of the compounds of formula I referred to the total lipid content of the organism used in the process are produced. Preferred starting material for the inventive process are linoleic acid (C18:2) and/or linolenic acid (C18:3) which are transformed to the preferred end products ARA or EPA. As for the inventive process organisms are used the product of the process is not a product of one pure substance per se. It is a mixture of different substances of formula I where one or more compounds are the major product and others are only contained as side products. In the event that in an organism used in the process linoleic and linolenic acid are available the end product is a mixture of ARA and EPA. Advantageously the side products shall not exceed 20 % by weight referred to the total lipid content of the organism, preferably the side products shall not exceed 15 % by weight, more preferably they shall not exceed 10 % by weight, most preferably they shall not exceed 5 % by weight. Preferably organisms are used in the process which contain as starting material either linoleic or linolenic acid so that as end product of the process only ARA or EPA are produced. In the event EPA and ARA are produced together, they should be produced in a ratio of at least 1:2 (EPA:ARA), preferably of at least 1:3, more preferably of at least 1:4, most preferably of at least 1:5. In the event that a mixture of different fatty acids such as ARA and EPA are the product of the inventive process said fatty acids can be further purified by method known by a person skilled in the art such as distillation, extraction, crystallization at low temperatures, chromatography or a combination of said methods.

**[0026]** In principle all host organisms can be used in the inventive process for example transgenic organisms such as plants like mosses; green, red, brown or blue algae; monocotyledons or dicotyledones. Advantageously oil producing Transgenic algae, mosses or plants are used in the inventive processes described herein (for the invention the singular shall include the plural and vice versa), Additional advantageously organisms are plants or parts thereof. Plants are preferably used, very particularly preferably plants such as oilseed plants containing high amounts of lipid compounds such as rapeseed, poppy, mustard, hemp, castor bean, sesame, olive, calendula, punica, hazel nut, almond, macadamia, avocado, pumpkin, walnut, laurel, pistachio, primrose, canola, peanut, linseed, soybean, safflower, sunflower, borage or plants such as maize, wheat, rye, oat, triticale, rice, barley, cotton, manihot, pepper, tagetes, solanaceous plants such as potato, tobacco, eggplant, and tomato, Vicia species, pea, alfalfa, bushy plants (coffee, cacao, tea), Salix species, trees (oil palm, coconut) and perennial grasses and forage crops. Particularly preferred plants of the invention are oilseed plants rapeseed, poppy, mustard, hemp, castor bean, sesame, olive, calendula, punica, hazel nut, almond, macadamia, avocado, pumpkin, laurel, pistachio, primrose, canola, peanut, linseed, soybean, safflower, sunflower, borage or trees (oil palm, coconut). Most preferred are C<sub>18:2</sub>- and/or C<sub>18:3</sub>-fatty acid rich plants such as hemp, sesame, linseed, poppy, pumpkin, walnut, tobacco, cotton, safflower or sunflower.

**[0027]** Depending on the nucleic acid and/or the organism used in the inventive processes different compounds of the general formula I can be synthesized. In addition depending on the plant used in the process different mixtures of formula I compounds or single compounds such as arachidonic acid or eicosapentaenoic acid in free or bound form can be produced. In the event that in the inventive processes organism are used which have as precursor of the fatty acid synthesis preferably C<sub>18:2</sub>- or C<sub>18:3</sub>-fatty acids different poly unsaturated fatty acids can be synthesized for example starting from C<sub>18:2</sub>-fatty acids  $\gamma$ -linoleic acid, dihomogamma-linoleic acid or arachidonic acid can be produced or starting from C<sub>18:3</sub>-fatty acids stearidonic acid, eicosatetraenoic acid or eicosapentaenoic acid can be produced. By influencing the activity of the different genes or their gene products different single compounds or compound mixtures can be produced. As living organisms are used in the inventive process the crude material that means crude lipids and/or oils isolated from the organisms preferably contain at least some starting compounds such as C<sub>18:2</sub>- or C<sub>18:3</sub>-fatty acids or their combination in the product and depending on the activity of the nucleic acid sequences and their gene products fatty acid intermediates of the biosynthesis chain. Said starting compounds or intermediates are in the product in a concentration of less than 20 or 15 % by weight, preferably less than 10, 9, 8, 7 or 6 % by weight, more preferably less than 5, 4, 3, 2 or 1 % by weight of the total fatty acids isolated from the used organism.

**[0028]** Transgenic plants are to be understood as meaning single plant cells and their cultures on solid media or in liquid culture, parts of plants and entire plants such as plant cell cultures, protoplasts from plants, callus cultures or plant

tissues such as leaves, shoots, seeds, flowers, roots etc. Said transgenic plants can be cultivated for example on solid or liquid culture medium, in soil or in hydroponics.

**[0029]** After cultivation transgenic plants which are used in the inventive process can be brought to the market without isolating compounds of the general formula I. Preferably the compounds of the general formula I are isolated from the organisms in the form of their free fatty acids, their lipids or oils. The purification can be done by conventional methods such as squeezing and extraction of the plants or other methods instead of the extraction such as distillation, crystallization at low temperatures, chromatography or a combination of said methods. Advantageously the plants are grinded, heated and/or vaporized before the squeezing and extraction procedure. As solvent for the extraction solvents such as hexane are used. The isolated oils are further purified by acidification with for example phosphoric acid. The free fatty acids are produced from said oils or lipids by hydrolysis. Charcoal or diatom earth are used to remove dyes from the fluid. In another preferred embodiment of the inventive process the alkyl ester of the fatty acids are produced from the oils and lipids by transesterification with an enzyme or with conventional chemistry. A preferred method is the production of the alkyl ester in the presence of alcoholates of the corresponding lower alcohols (C1 to C10 alcohols such as methanol, ethanol, propanol, butanol, hexanol etc.) such as methanolate or ethanolate. Therefore as the skilled worker knows the alcohol in the presence of a catalytic amount of a base such as NaOH or KOH is added to the oils or lipids.

**[0030]** It is also disclosed that the lipids can be obtained in the usual manner after the organisms have been grown. To this end, the organisms can first be harvested and then disrupted, or they can be used directly. It is advantageous to extract the lipids with suitable solvents such as apolar solvents, for example hexane, or polar solvents, for example ethanol, isopropanol, or mixtures such as hexane/isopropanol, phenol/chloroform/isoamyl alcohol, at temperatures between 0°C and 80°C, preferably between 20°C and 50°C. As a rule, the biomass is extracted with an excess of solvent, for example with an excess of solvent to biomass of 1:4. The solvent is subsequently removed, for example by distillation. The extraction may also be carried out with supercritical CO<sub>2</sub>. After the extraction, the remainder of the biomass can be removed, for example, by filtration. Standard methods for the extraction of fatty acids from plants and microorganisms are described in Bligh et al. (Can. J. Biochem. Physiol. 37, 1959: 911-917) or Vick et al. (Plant Physiol. 69, 1982:1103-1108).

**[0031]** The crude oil thus obtained can then be purified further, for example by removing cloudiness by adding polar solvents such as acetone or apolar solvents such as chloroform, followed by filtration or centrifugation. Further purification via columns or other techniques is also possible.

**[0032]** To obtain the free fatty acids from the triglycerides, the latter are hydrolyzed in the customary manner, for example using NaOH or KOH.

**[0033]** In the process oils, lipids and/or free fatty acids or fractions thereof are produced. Said products can be used for the production of feed and food products, cosmetics or pharmaceuticals.

**[0034]** In principle all nucleic acids encoding polypeptides with  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase activity can be used in the inventive process. Preferably the nucleic acid sequences can be isolated for example from microorganism or plants such as fungi like *Mortierella*, algae like *Euglena*, *Cryptocodium* or *Isochrysis*, diatoms like *Phaeodactylum* or mosses like *Physcomitrella* or *Ceratodon*, but also non-human animals such as *Caenorhabditis* are possible as source for the nucleic acid sequences. Advantageous nucleic acid sequences which encode polypeptides having a  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase activity are originate from microorganisms or plants, advantageously *Phaeodactylum tricomutum*, *Ceratodon purpureus*, *Physcomitrella patens*, *Euglena gracilis* or *Isochrysis galbana*. *Euglena gracilis* or *Isochrysis galbana* are specific for the conversion of  $\omega$ -3- or  $\omega$ -6 fatty acids. Thus, the co expression of a  $\Delta$ -9 elongase and a C20-specific  $\Delta$ -8-desaturase leads to the formation of eicosatrienoic acid (C20:6n-3,  $\Delta$ 8, 11, 14) and eicosatetraenoic acid (C20:3n-4,  $\Delta$ 8, 11, 14, 17). Co-expression of a third gene coding for a C20- $\Delta$ 5 specific desaturase leads to the production of Arachidonic acid (C20:6n-4,  $\Delta$ 5, 8, 11, 14) or Eicosapentaenoic acid (C20:3n-5,  $\Delta$ 5, 8, 11, 14, 17).

**[0035]** The invention discloses the nucleotide sequence SEQ ID, No: 1 and the polypeptide sequence SEQ ID No: 2. Derivative(s) of the sequences according to the invention are for example, functional homologues of the polypeptides or enzymes encoded by SEQ ID NO: 2, but are not part of the invention. Also disclosed are derivatives of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10 which exhibit the same said specific enzymatic activity, but are not part of the invention. This specific enzymatic activity allows advantageously the synthesis of unsaturated fatty acids having more than three double bonds in the fatty acid molecule. By unsaturated fatty acids is meant in what follows diunsaturated or polyunsaturated fatty acids which possess double bonds. The double bonds may be conjugated or non conjugated. The said sequences encode enzymes which exhibit  $\Delta$ -9 elongase,  $\Delta$ -8-desaturase or  $\Delta$ -5-desaturase activity.

**[0036]** The enzymes,  $\Delta$ -9 elongase,  $\Delta$ -8-desaturase or  $\Delta$ -5-desaturase, advantageously either elongates fatty acid chains with 18 carbon atoms (see SEQ ID NO: 2) or introduces a double bond into fatty acid residues of glycerolipids, free fatty acids or acyl-CoA fatty acids at position C<sub>8</sub>-C<sub>9</sub> (see SEQ ID NO: 4) or at position C<sub>5</sub>-C<sub>6</sub> (see SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10).

**[0037]** The nucleic acid sequence(s) according to the invention (for purposes of the application the singular encompasses the plural and vice versa) or fragments thereof may advantageously be used for isolating other genomic sequences

via homology screening.

**[0038]** Allele variants include in particular functional variants obtainable by deletion, insertion or substitution of nucleotides in the sequences depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 the enzymatic activity of the derived synthesized proteins being retained.

**[0039]** Starting from the DNA sequence described in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 or parts of said sequences such DNA sequences can be isolated using, for example, normal hybridization methods or the PCR technique from other eukaryotes such as those identified above for example. These DNA sequences hybridize under standard conditions with the said sequences. For hybridization use is advantageously made of short oligonucleotides of the conserved regions of an average length of about 15 to 70 bp, preferably of about 17 to 60 bp, more preferably of about 19 to 50 bp, most preferably of about 20 to 40 bp, for example, which can be determined by comparisons with other desaturase or elongase genes in the manner known to those skilled in the art. The histidine box sequences are advantageously employed. However, longer fragments of the nucleic acids according to the invention or the complete sequences may also be used for hybridization. Depending on the nucleic acid employed: oligonucleotide, longer fragment or complete sequence, or depending on which type of nucleic acid, DNA or RNA, is used for hybridization these standard conditions vary. Thus, for example, the melting temperatures of DNA:DNA hybrids are approximately 10 °C lower than those of DNA:RNA hybrids of the same length.

**[0040]** By standard conditions is meant, for example, depending on the nucleic acid in question temperatures between 42 °C and 58 °C in an aqueous buffer solution having a concentration of between 0.1 and 5 x SSC (1 X SSC = 0.15 M NaCl, 15 mM sodium citrate, pH 7.2) or additionally in the presence of 50 % formamide, such as by way of example 42 °C in 5 x SSC, 50 % formamide. Hybridization conditions for DNA:DNA hybrids are advantageously 0.1 x SSC and temperatures between approximately 20 °C and 45 °C, preferably between approximately 30 °C and 45 °C. For DNA:RNA hybrids the hybridization conditions are advantageously 0.1 x SSC and temperatures between approximately 30 °C and 55 °C, preferably between approximately 45 °C and 55 °C. These specified temperatures for hybridization are melting temperature values calculated by way of example for a nucleic acid having a length of approximately 100 nucleotides and a G + C content of 50 % in the absence of formamide. The experimental conditions for DNA hybridization are described in relevant genetics textbooks such as by way of example Sambrook et al., "Molecular Cloning", Cold Spring Harbor Laboratory, 1989, and may be calculated by formulae known to those skilled in the art, for example as a function of the length of the nucleic acids, the nature of the hybrids or the G + C content. Those skilled in the art may draw on the following textbooks for further information on hybridization: Ausubel et al. (eds), 1985, Current Protocols in Molecular Biology, John Wiley & Sons, New York; Hames and Higgins (eds), 1985, Nucleic Acids Hybridization: A Practical Approach, IRL Press at Oxford University Press, Oxford; Brown (ed), 1991, Essential Molecular Biology: A Practical Approach, IRL Press at Oxford University Press, Oxford.

**[0041]** By homologues of the sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 9 is meant derivatives such as by way of example promoter variants. These variants may be modified by one or more nucleotide exchanges, by insertion(s) and/or deletion(s) without, however, adversely affecting the functionality or efficiency of the promoters. Furthermore, the promoters can have their efficiency increased by altering their sequence or be completely replaced by more effective promoters even of foreign organisms.

**[0042]** By derivatives is advantageously meant variants whose nucleotide sequence has been altered in the region from -1 to -2000 ahead of the start codon in such a way that the gene expression and/or the protein expression is modified, preferably increased. Furthermore, by derivatives is also meant variants which have been modified at the 3' end.

**[0043]** The nucleic acid sequences according to the invention which encode a  $\Delta$ -8-desaturase, a  $\Delta$ -5-desaturase and/or a  $\Delta$ -9-elongase may be produced by synthesis or obtained naturally or contain a mixture of synthetic and natural DNA components as well as consist of various heterologous  $\Delta$ -8-desaturase,  $\Delta$ -5-desaturase and/or  $\Delta$ -9-elongase gene segments from different organisms. In general, synthetic nucleotide sequences are produced with codons which are preferred by the corresponding host organisms, plants for example. This usually results in optimum expression of the heterologous gene. These codons preferred by plants may be determined from codons having the highest protein frequency which are expressed in most of the plant species of interest. An example concerning *Corynebacterium glutamicum* is provided in Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such experiments can be carried out using standard methods and are known to the person skilled in the art.

**[0044]** In addition, artificial DNA sequences are suitable, provided, as described above, they mediate the desired property, for example an increase in the content of  $\Delta$ -8 and/or  $\Delta$ -5 double bonds in fatty acids, oils or lipids in organisms such as in a plant by over-expression of the  $\Delta$ -8-and/or  $\Delta$ -5-desaturase gene in preferably in crop plants. Such artificial DNA sequences can exhibit  $\Delta$ -8 and/or  $\Delta$ -5-desaturase and/or  $\Delta$ -9-elongase activity, for example by back-translation of proteins constructed by means of molecular modeling, or be determined by in vitro selection. Possible techniques for in vitro evolution of DNA to modify or improve the DNA sequences are described in Patten, P.A. et al., Current Opinion in Biotechnology 8, 724-733(1997) or in Moore, J.C. et al., Journal of Molecular Biology 272, 336-347 (1997). Particularly suitable are encoding DNA sequences which are obtained by back-translation of a polypeptide sequence in accordance with the codon use specific to the host plant. Those skilled in the art familiar with the methods of plant genetics can



easily determine the specific codon use by computer analyses of other known genes of the plant to be transformed.

**[0045]** Other suitable equivalent nucleic acid sequences which may be mentioned are sequences that encode fusion proteins, a component of the fusion protein being a  $\Delta$ -8-and/or a  $\Delta$ -5-desaturase polypeptide and/or a  $\Delta$ -9 elongase polypeptide or a functionally equivalent part thereof. The second part of the fusion protein can be, for example, another polypeptide having enzymatic activity or an antigenic polypeptide sequence by means of which it is possible to demonstrate  $\Delta$ -8- and/or  $\Delta$ -5-desaturase or  $\Delta$ -9-elongase expression (e.g. myc tag or his tag). Preferably, however, this is a regulatory protein sequence, such as by way of example a signal sequence for the endoplasmic reticulum (= ER) which directs the  $\Delta$ -8- and/or  $\Delta$ -5-desaturase protein and/or the  $\Delta$ -9-elongase protein to the desired point of action, or regulatory sequences which influence the expression of the nucleic acid sequence according to the invention, such as promoters or terminators. In another preferred embodiment the second part of the fusion protein is a plastidial targeting sequence as described by Napier J.A. [Targeting of foreign proteins to the chloroplast, *Methods Mol. Biol.*, 49, 1995: 369 - 376]. A preferred used vector comprising said plastidial targeting sequence is disclosed by Colin Lazarus [Guerineau F., Woolston S., Brooks L., Mullineaux P. "An expression cassette for targeting foreign proteins into chloroplast; *Nucleic Acids Res.*, Dec 9, 16 (23), 1988: 11380].

**[0046]** Advantageously, the  $\Delta$ -8-desaturase and  $\Delta$ -9-elongase and/or the  $\Delta$ -5-desaturase genes in the method according to the invention may be combined with other genes for fatty acid biosynthesis. Examples of such genes are the acyl transferases, other desaturases or elongases such as  $\Delta$ -4-,  $\Delta$ -5- or  $\Delta$ -6-desaturases or  $\omega$ -3- and/or  $\omega$ -6-specific desaturases such as  $\Delta$ -12 (for  $C_{18}$  fatty acids),  $\Delta$ -15 (for  $C_{18}$  fatty acids) or  $\Delta$ -19 (for  $C_{22}$  fatty acids) and/or such as  $\Delta$ -5- or  $\Delta$ -6-elongases. For in vivo and especially in vitro synthesis combination with e.g. NADH cytochrome B5 reductases which can take up or release reduction equivalents is advantageous.

**[0047]** By the amino acid sequences according to the invention is meant proteins which contain an amino acid sequence depicted in the sequence SEQ ID NO: 2. Also disclosed are the sequences SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10. For the estimation of an enzymatic activity which is "not substantially reduced" or which has the "same enzymatic activity" the enzymatic activity of the derived sequences are determined and compared with the wild type enzyme activities. In doing this, for example, certain amino acids may be replaced by others having similar physicochemical properties (space filling, basicity, hydrophobicity, etc.). For example, arginine residues are exchanged for lysine residues, valine residues for isoleucine residues or aspartic acid residues for glutamic acid residues. However, one or more amino acids may also be swapped in sequence, added or removed, or a plurality of these measures may be combined with one another. The present invention also encompasses those nucleotide sequences which are obtained by modification of the  $\Delta$ -8-desaturase nucleotide sequence, the  $\Delta$ -5-desaturase nucleotide sequence and/or the  $\Delta$ -9-elongase nucleotide sequence used in the inventive processes. The aim of such a modification may be, e.g., to further bound the encoding sequence contained therein or also, e.g., to insert further restriction enzyme interfaces.

**[0048]** Functional equivalents also include those variants whose function by comparison as described above with the initial gene or gene fragment is weakened (= not substantially reduced) or reinforced (= enzyme activity higher than the activity of the initial enzyme, that is activity is higher than 100 %, preferably higher than 110 %, particularly preferably higher than 130 %).

**[0049]** At the same time the nucleic acid sequence may, for example, advantageously be a DNA or cDNA sequence. Suitable encoding sequences for insertion into an expression cassette according to the invention include by way of example those which encode a  $\Delta$ -8-desaturase, a  $\Delta$ -5-desaturase and/or a  $\Delta$ -9-elongase with the sequences described above and lend the host the ability to overproduce fatty acids, oils or lipids having double bonds in the  $\Delta$ -8-position and  $\Delta$ -5-position, it being advantageous when at the same time fatty acids having at least four double bonds are produced. These sequences may be of homologous or heterologous origin.

**[0050]** By the expression cassette (= nucleic acid construct or fragment or gene construct) according to the invention is meant the sequences specified in SEQ ID NO: 1. Also disclosed are expression cassette with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 and/or SEQ ID NO: 9 which result from the genetic code and/or derivatives thereof which are functionally linked with one or more regulation signals advantageously to increase the gene expression and which control the expression of the encoding sequence in the host cell. These regulatory sequences should allow the selective expression of the genes and the protein expression. Depending on the host organism this may mean, for example, that the gene is expressed and/or overexpressed only after induction or that it is expressed and/or overexpressed immediately. Examples of these regulatory sequences are sequences to which inducers or repressors bind and in this way regulate the expression of the nucleic acid. In addition to these new regulation sequences or instead of these sequences the natural regulation of these sequences ahead of the actual structural genes may still be present and optionally have been genetically modified so that natural regulation was switched off and the expression of the genes increased. However, the gene construct can also be built up more simply, that is no additional regulation signals have been inserted ahead of the nucleic acid sequence or derivatives thereof and the natural promoter with its regulation has not been removed. Instead of this the natural regulation sequence was mutated in such a way that no further regulation ensues and/or the gene expression is heightened. These modified promoters in the form of part sequences (= promoter containing parts of the nucleic acid sequences according to the invention) can also be brought on their own ahead of the natural gene

to increase the activity. In addition, the gene construct may advantageously also contain one or more so-called enhancer sequences functionally linked to the promoter which allow enhanced expression of the nucleic acid sequence. At the 3' end of the DNA sequences additional advantageous sequences may also be inserted, such as further regulatory elements or terminators. The  $\Delta$ -8- and/or  $\Delta$ -5-desaturase gene and/or the  $\Delta$ -9-elongase gene may be present in one or more copies in the expression cassette (= gene construct).

**[0051]** As described above, the regulatory sequences or factors can preferably positively influence and so increase the gene expression of the introduced genes. Thus, reinforcement of the regulatory elements advantageously on the transcription level may be effected by using powerful transcription signals such as promoters and/or enhancers. However, in addition reinforcement of translation is also possible, for example by improving the stability of the mRNA.

**[0052]** Suitable promoters in the expression cassette are in principle all promoters which can control the expression of foreign genes in organisms such as microorganisms like protozoa such as ciliates, algae such as green, brown, red or blue algae such as Euglenia, bacteria such as gram-positive or gram-negative bacteria, yeasts such as Saccharomyces, Pichia or Schizosaccharomyces or fungi such as Mortierella, Thraustochytrium or Schizochytrium or plants such as Aleuritia, advantageously in plants or fungi. Use is preferably made in particular of plant promoters or promoters derived from a plant virus. Advantageous regulation sequences for the method according to the invention are found for example in promoters such as cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, lacI<sup>q</sup>, T7, T5, T3, gal, trc, ara, SP6,  $\lambda$ -P<sub>R</sub> or in  $\lambda$ -P<sub>L</sub> promoters which are employed advantageously in gram-negative bacteria. Other advantageous regulation sequences are found, for example, in the gram-positive promoters amy and SPO2, in the yeast or fungal promoters ADC1, MF $\alpha$ , AC, P-60, CYC1, GAPDH, TEF, rp28, ADH or in the plant promoters CaMV/35S [Franck et al., Cell 21(1980) 285-294], SSU, OCS, lib4, STLS1, B33, nos (= Nopalin Synthase Promoter) or in the ubiquitin or phaseolin promoter. The expression cassette may also contain a chemically inducible promoter by means of which the expression of the exogenous  $\Delta$ 8- and/or  $\Delta$ -5-desaturase gene and/or the  $\Delta$ -9-elongase gene in the organisms can be controlled advantageously in the plants at a particular time. Advantageous plant promoters of this type are by way of example the PRP1 promoter [Ward et al., Plant. Mol. Biol.22(1993), 361-366], a promoter inducible by benzenesulfonamide (EP 388 186), a promoter inducible by tetracycline [Gatz et al., (1992) Plant J. 2,397-404], a promoter inducible by salicylic acid (WO 95/19443), a promoter inducible by abscisic acid (EP 335 528) and a promoter inducible by ethanol or cyclohexanone (WO93/21334). Other examples of plant promoters which can advantageously be used are the promoter of cytosolic FBpase from potato, the ST-LSI promoter from potato (Stockhaus et al., EMBO J. 8 (1989) 2445-245), the promoter of phosphoribosyl pyrophosphate amidotransferase from Glycine max (see also gene bank accession number U87999) or a nodiene-specific promoter as described in EP 249 676. Particularly advantageous are those plant promoters which ensure expression in tissues or plant parts/organs in which fatty acid biosynthesis or the precursor stages thereof occurs, as in endosperm or in the developing embryo for example. Particularly noteworthy are advantageous promoters which ensure seed-specific expression such as by way of example the USP promoter or derivatives thereof, the LeB4 promoter, the phaseolin promoter or the napin promoter. The particularly advantageous USP promoter cited according to the invention or its derivatives mediate very early gene expression in seed development [Baeumlein et al., Mol Gen Genet, 1991, 225 (3): 459-67]. Other advantageous seed-specific promoters which may be used for monocotyledonous or dicotyledonous plants are the promoters suitable for dicotyledons such as napin gene promoters, likewise cited by way of example, from oilseed rape (US 5,608,152), the oleosin promoter from Arabidopsis (WO 98/45461), the phaseolin promoter from Phaseolus vulgaris (US 5,504,200), the Bce4 promoter from Brassica (WO 91/13980) or the leguminous B4 promoter (LeB4, Baeumlein et al., Plant J., 2, 2, 1992: 233-239) or promoters suitable for monocotyledons such as the promoters of the lpt2 or lpt1 gene in barley (WO 95/15389 and WO 95/23230) or the promoters of the barley hordeine gene, the rice glutelin gene, the rice oryzin gene, the rice prolamin gene, the wheat gliadin gene, the white glutelin gene, the corn zein gene, the oats glutelin gene, the sorghum kasirin gene or the rye secalin gene which are described in WO99/16890.

**[0053]** Furthermore, particularly preferred are those promoters which ensure the expression in tissues or plant parts in which, for example, the biosynthesis of fatty acids, oils and lipids or the precursor stages thereof takes place. Particularly noteworthy are promoters which ensure a seed-specific expression. Noteworthy are the promoter of the napin gene from oilseed rape (US 5,608,152), the USP promoter from Vicia faba (USP = unknown seed protein, Baeumlein et al., Mol Gen Genet, 1991, 225 (3): 459-67), the promoter of the oleosin gene from Arabidopsis (WO98/45461), the phaseolin promoter (US 5,504,200) or the promoter of the legumin B4 gene (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2): 233-9). Other promoters to be mentioned are that of the lpt2 or lpt1 gene from barley (WO95/15389 and WO95/23230) which mediate seed-specific expression in monocotyledonous plants. Other advantageous seed specific promoters are promoters such as the promoters from rice, corn or wheat disclosed in WO 99/16890 or Amy32b, Amy6-6 or aleurain (US 5,677,474), Bce4 (rape, US 5,530,149), glycinin (soy bean, EP 571 741), phosphoenol pyruvat carboxyl-ase (soy bean, JP 06/62870), ADR12-2 (soy bean, WO 98/08962), isocitratlyase (rape, US 5,689,040) or  $\beta$ -amylase (barley, EP 781 849).

**[0054]** As described above, the expression construct (= gene construct, nucleic acid construct) may contain yet other genes which are to be introduced into the organisms. These genes can be subject to separate regulation or be subject

to the same regulation region as the  $\Delta$ -8- and/or  $\Delta$ -5-desaturase gene and/or the  $\Delta$ -9-elongase gene. These genes are by way of example other biosynthesis genes, advantageously for fatty acid biosynthesis, which allow increased synthesis. Examples which may be mentioned are the genes form  $\Delta$ -15-  $\Delta$ -12-,  $\Delta$ -9-,  $\Delta$ -5-,  $\Delta$ -4-desaturase,  $\alpha$ -ketoacyl reductases,  $\alpha$ -ketoacyl synthases, elongases or the various hydroxylases and acyl-ACP thioesterases. The desaturase genes are advantageously used in the nucleic acid construct.

**[0055]** In principle all natural promoters with their regulation sequences can be used like those named above for the expression cassette according to the invention and the method according to the invention. Over and above this, synthetic promoters may also advantageously be used.

**[0056]** In the preparation of an expression cassette various DNA fragments can be manipulated in order to obtain a nucleotide sequence which usefully reads in the correct direction and is equipped with a correct reading raster. To connect the DNA fragments (= nucleic acids according to the invention) to one another adaptors or linkers may be attached to the fragments.

**[0057]** The promoter and the terminator regions can usefully be provided in the transcription direction with a linker or polylinker containing one or more restriction points for the insertion of this sequence. Generally, the linker has 1 to 10, mostly 1 to 8, preferably 2 to 6, restriction points. In general the size of the linker inside the regulatory region is less than 100 bp, frequently less than 60 bp, but at least 5 bp. The promoter may be both native or homologous as well as foreign or heterologous to the host organism, for example to the host plant. In the 5'-3' transcription direction the expression cassette contains the promoter, a DNA sequence which encodes a  $\Delta$ -8-desaturase gene, a  $\Delta$ -5-desaturase gene and/or a  $\Delta$ -9-elongase gene and a region for transcription termination. Different termination regions can be exchanged for one another in any desired fashion.

**[0058]** Furthermore, manipulations which provide suitable restriction interfaces or which remove excess DNA or restriction interfaces can be employed. Where insertions, deletions or substitutions, such as transitions and transversions, come into consideration, *in vitro* mutagenesis, primer repair, restriction or ligation may be used. In suitable manipulations such as restriction, chewing back or filling of overhangs for blunt ends complementary ends of the fragments can be provided for the ligation.

**[0059]** For an advantageous high expression the attachment of the specific ER retention signal SEKDEL inter alia can be of importance (Schouten, A. et al., Plant Mol. Biol. 30 (1996), 781-792). In this way the average expression level is tripled or even quadrupled. Other retention signals which occur naturally in plant and animal proteins located in the ER may also be employed for the construction of the cassette. In another preferred embodiment a plastidial targeting sequence is used as described by Napier J.A. [Targeting of foreign proteins to the chloroplast, Methods Mol. Biol., 49, 1995: 369-376]. A preferred used vector comprising said plastidial targeting sequence is disclosed by Colin Lazarus [Guerineau F., Woolston S., Brooks L., Mullineaux P. "An expression cassette for targeting foreign proteins into chloroplast; Nucleic. Acids Res., Dec 9, 16 (23), 1988: 11380].

**[0060]** Preferred polyadenylation signals are plant polyadenylation signals, preferably those which substantially correspond to T-DNA polyadenylation signals from *Agrobacterium tumefaciens*, in particular gene 3 of the T-DNA (octopine synthase) of the Ti plasmid pTiACH5 (Gielen et al., EMBO J.3 (1984), 835 et seq.) or corresponding functional equivalents.

**[0061]** An expression cassette is produced by fusion of a suitable promoter with a suitable  $\Delta$ -8- and/or  $\Delta$ -5-desaturase DNA sequence and/or a suitable  $\Delta$ -9-elongase DNA sequence together with a polyadenylation signal by common recombination and cloning techniques as described, for example, in T. Maniatis, E.F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) as well as in T.J. Silhavy, M.L. Berman and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and in Ausubel, F.M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley-Interscience (1987).

**[0062]** In the preparation of an expression cassette various DNA fragments can be manipulated to produce a nucleotide sequence which usefully reads in the correct direction and is equipped with a correct reading raster. Adapters or linkers can be attached to the fragments for joining the DNA fragments.

**[0063]** The promoter and the terminator regions can usefully be provided in the transcription direction with a linker or polylinker containing one or more restriction points for the insertion of this sequence. Generally, the linker has 1 to 10, mostly 1 to 8, preferably 2 to 6, restriction points. In general the size of the linker inside the regulatory region is less than 100 bp, frequently less than 60 bp, but at least 5 bp. The promoter may be both native or homologous as well as foreign or heterologous to the host organism, for example to the host plant. In the 5'-3' transcription direction the expression cassette contains the promoter, a DNA sequence which either encodes a  $\Delta$ -8- and/or  $\Delta$ -5-desaturase gene and/or a  $\Delta$ -9-elongase gene and a region for transcription termination. Different termination regions can be exchanged for one another in any desired fashion.

**[0064]** In the preparation of an expression cassette various DNA fragments can be manipulated to produce a nucleotide sequence which usefully reads in the correct direction and is equipped with a correct reading raster. Adapters or linkers can be attached to the fragments for joining the DNA fragments.

**[0065]** The DNA sequences encoding the nucleic acid sequences used in the inventive processes such as the  $\Delta$ -8-

desaturase from *Euglenia gracilis*, the  $\Delta$ -9-elongase from *Isochrysis galbana* and/or the  $\Delta$ -5-desaturase for example from *Caenorhabditis elegans*, *Mortierella alpina*, *Borage officinalis* or *Physcomitrella patens* contain all the sequence characteristics needed to achieve correct localization of the site of fatty acid, lipid or oil biosynthesis. Accordingly, no further targeting sequences are needed per se. However, such a localization may be desirable and advantageous and hence artificially modified or reinforced so that such fusion constructs are also a preferred advantageous embodiment of the invention.

**[0066]** Particularly preferred are sequences which ensure targeting in plastids. Under certain circumstances targeting into other compartments (reported in: Kermode, Crit. Rev. Plant Sci. 15, 4 (1996), 285-423) may also be desirable, e.g. into vacuoles, the mitochondrion, the endoplasmic reticulum (ER), peroxisomes, lipid structures or due to lack of corresponding operative sequences retention in the compartment of origin, the cytosol.

**[0067]** Advantageously, the nucleic acid sequences according to the invention or the gene construct together with at least one reporter gene are cloned into an expression cassette which is introduced into the organism via a vector or directly into the genome. This reporter gene should allow easy detection via a growth, fluorescence, chemical, bioluminescence or resistance assay or via a photometric measurement. Examples of reporter genes which may be mentioned are antibiotic- or herbicide-resistance genes, hydrolase genes, fluorescence protein genes, bioluminescence genes, sugar or nucleotide metabolic genes or biosynthesis genes such as the Ura3 gene, the *Ilv2* gene, the luciferase gene, the  $\beta$ -galactosidase gene, the *gfp* gene, the 2-desoxyglucose-6-phosphate phosphatase gene, the  $\beta$ -glucuronidase gene,  $\beta$ -lactamase gene, the neomycin phosphotransferase gene, the hygromycin phosphotransferase gene or the BASTA (= glutaminate-resistance) gene. These genes permit easy measurement and quantification of the transcription activity and hence of the expression of the genes. In this way genome positions may be identified which exhibit differing productivity.

**[0068]** In a preferred embodiment an expression cassette comprises upstream, i.e. at the 5' end of the encoding sequence, a promoter and downstream, i.e. at the 3' end, a polyadenylation signal and optionally other regulatory elements which are operably linked to the intervening encoding sequence for  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase DNA sequence. By an operable linkage is meant the sequential arrangement of promoter, encoding sequence, terminator and optionally other regulatory elements in such a way that each of the regulatory elements can fulfill its function in the expression of the encoding sequence in due manner. The sequences preferred for operable linkage are targeting sequences for ensuring subcellular localization in plastids. However, targeting sequences for ensuring subcellular localization in the mitochondrion, in the endoplasmic reticulum (= ER), in the nucleus, in oil corpuscles or other compartments may also be employed as well as translation promoters such as the 5' lead sequence in tobacco mosaic virus (Gallie et al., Nucl. Acids Res. 15 (1987), 8693 -8711).

**[0069]** An expression cassette may, for example, contain a constitutive promoter or a tissue-specific promoter (preferably the USP or napin promoter) the gene to be expressed and the ER retention signal. For the ER retention signal the KDEL amino acid sequence (lysine, aspartic acid, glutamic acid, leucine) or the KKX amino acid sequence (lysine-lysine-X-stop, wherein X means every other known amino acid) is preferably employed.

**[0070]** For expression in a prokaryotic or eukaryotic host organism, for example a microorganism such as a fungus or a plant the expression cassette is advantageously inserted into a vector such as by way of example a plasmid, a phage or other DNA which allows optimum expression of the genes in the host organism. Examples of suitable plasmids are: in *E. coli* pLG338, pACYC184, pBR series such as e.g. pBR322, pUC series such as pUC18 or pUC19, M113mp series, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III<sup>113</sup>-B1,  $\lambda$ gt11 or pBdCl; in *Streptomyces* pIJ101, pIJ364, pIJ702 or pIJ361; in *Bacillus* pUB110, pC194 or pBD214; in *Corynebacterium* pSA77 or pAJ667; in fungi pALS1, pIL2 or pBB116; other advantageous fungal vectors are described by Romanos, M.A. et al., [(1992) "Foreign gene expression in yeast: a review", *Yeast* 8: 423-488] and by van den Hondel, C.A.M.J.J. et al. [(1991) "Heterologous gene expression in filamentous fungi" as well as in *More Gene Manipulations in Fungi* [J.W. Bennet & L.L. Lasure, eds., pp. 396-428: Academic Press: San Diego] and in "Gene transfer systems and vector development for filamentous fungi" [van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) in: *Applied Molecular Genetics of Fungi*, Peberdy, J.F. et al., eds., pp. 1-28, Cambridge University Press: Cambridge]. Examples of advantageous yeast promoters are 2 $\mu$ M, pAG-1, YEp6, YEp13 or pEMBLye23. Examples of algal or plant promoters are pLGV23, pGHlac<sup>+</sup>, pBIN19, pAK2004, pVKH or pDH51 (see Schmidt, R. and Willmitzer, L., 1988). The vectors identified above or derivatives of the vectors identified above are a small selection of the possible plasmids. Further plasmids are well known to those skilled in the art and may be found, for example, in the book *Cloning Vectors* (Eds. Pouwels P.H. et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018). Suitable plant vectors are described inter alia in "Methods in Plant Molecular Biology and Biotechnology" (CRC Press), Ch. 6/7, pp. 71-119. Advantageous vectors are known as shuttle vectors or binary vectors which replicate in *E. coli* and *Agrobacterium*.

**[0071]** By vectors is meant with the exception of plasmids all other vectors known to those skilled in the art such as by way of example phages, viruses such as SV40, CMV, baculovirus, adenovirus, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA. These vectors can be replicated autonomously in the host organism or be chromosomally replicated, chromosomal replication being preferred.

**[0072]** In a further embodiment of the vector the expression cassette according to the invention may also advantageously be introduced into the organisms in the form of a linear DNA and be integrated into the genome of the host organism by way of heterologous or homologous recombination. This linear DNA may be composed of a linearized plasmid or only of the expression cassette as vector or the nucleic acid sequences according to the invention.

**[0073]** In a further advantageous embodiment the nucleic acid sequence according to the invention can also be introduced into an organism on its own.

**[0074]** If in addition to the nucleic acid sequence according to the invention further genes are to be introduced into the organism, all together with a reporter gene in a single vector or each single gene with a reporter gene in a vector in each case can be introduced into the organism, whereby the different vectors can be introduced simultaneously or successively.

**[0075]** The vector advantageously contains at least one copy of the nucleic acid sequences according to the invention and/or the expression cassette (= gene construct) according to the invention.

**[0076]** By way of example the plant expression cassette can be installed in the pRT transformation vector ((a) Toepfer et al., 1993, *Methods Enzymol.*, 217: 66-78; (b) Toepfer et al. 1987, *Nucl. Acids. Res.* 15: 5890 ff.).

**[0077]** Alternatively, a recombinant vector (= expression vector) can also be transcribed and translated in vitro, e.g. by using the T7 promoter and the T7 RNA polymerase.

**[0078]** Expression vectors employed in prokaryotes frequently make use of inducible systems with and without fusion proteins or fusion oligopeptides, wherein these fusions can ensue in both N-terminal and C-terminal manner or in other useful domains of a protein. Such fusion vectors usually have the following purposes: i.) to increase the RNA expression rate; ii.) to increase the achievable protein synthesis rate; iii.) to increase the solubility of the protein; iv.) or to simplify purification by means of a binding sequence usable for affinity chromatography. Proteolytic cleavage points are also frequently introduced via fusion proteins which allows cleavage of a portion of the fusion protein and purification. Such recognition sequences for proteases are recognized, e.g. factor Xa, thrombin and enterokinase.

**[0079]** Typical advantageous fusion and expression vectors are pGEX [Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67: 31-40], pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which contains glutathione S-transferase (GST), maltose binding protein or protein A.

**[0080]** Other examples of *E. coli* expression vectors are pTrc [Amann et al., (1988) *Gene* 69:301-315] and pET vectors [Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89; Stratagene, Amsterdam, The Netherlands].

**[0081]** Other advantageous vectors for use in yeast are pYepSec1 (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), and pYES derivatives (Invitrogen Corporation, San Diego, CA). Vectors for use in filamentous fungi are described in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi", in: *Applied Molecular Genetics of Fungi*, J.F. Peberdy, et al., eds., pp. 1-28, Cambridge University Press: Cambridge.

**[0082]** Alternatively, insect cell expression vectors can also be advantageously utilized, e.g. for expression in Sf 9 cells. These are e.g. the vectors of the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

**[0083]** Furthermore, plant cells or algal cells can advantageously be used for gene expression. Examples of plant expression vectors may be found in Becker, D., et al. (1992) "New plant binary vectors with selectable markers located proximal to the left border", *Plant Mol. Biol.* 20: 1195-1197 or in Bevan, M.W. (1984) "Binary *Agrobacterium* vectors for plant transformation", *Nucl. Acid. Res.* 12: 8711-8721.

**[0084]** Furthermore, the nucleic acid sequences may also be expressed in mammalian cells, advantageously in non-human mammalian cells. Examples of corresponding expression vectors are pCDM8 and pMT2PC referred to in: Seed, B. (1987) *Nature* 329:840 or Kaufman et al. (1987) *EMBO J.* 6: 187-195). At the same time promoters preferred for use are of viral origin, such as by way of example promoters of polyoma, adenovirus 2, cytomegalovirus or simian virus 40. Other prokaryotic and eukaryotic expression systems are referred to in chapters 16 and 17 of Sambrook et al., *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

**[0085]** The host organism (= transgenic organism) advantageously contains at least one copy of the nucleic acid according to the invention and/or of the nucleic acid construct according to the invention.

**[0086]** The introduction of the nucleic acids according to the invention, the expression cassette or the vector into organisms, plants for example, can in principle be done by all of the methods known to those skilled in the art. The introduction of the nucleic acid sequences gives rise to recombinant or transgenic organisms.

**[0087]** In the case of microorganisms, those skilled in the art can find appropriate methods in the textbooks by Sambrook, J. et al. (1989) *Molecular cloning: A laboratory manual*, Cold Spring Harbor Laboratory Press, by F.M. Ausubel et al. (1994) *Current protocols in molecular biology*, John Wiley and Sons, by D.M. Glover et al., *DNA Cloning Vol.1*, (1995), IRL Press (ISBN 019-963476-9), by Kaiser et al. (1994) *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory Press or Guthrie et al. *Guide to Yeast Genetics and Molecular Biology*, *Methods in Enzymology*, 1994, Academic Press.

**[0088]** The transfer of foreign genes into the genome of a plant is called transformation. In doing this the methods

described for the transformation and regeneration of plants from plant tissues or plant cells are utilized for transient or stable transformation. Suitable methods are protoplast transformation by poly(ethylene glycol)-induced DNA uptake, the "biolistic" method using the gene cannon - referred to as the particle bombardment method, electroporation, the incubation of dry embryos in DNA solution, microinjection and gene transfer mediated by *Agrobacterium*. Said methods are described by way of example in B. Jenes et al., *Techniques for Gene Transfer*, in: *Transgenic Plants*, Vol. 1, Engineering and Utilization, eds. S.D. Kung and R. Wu, Academic Press (1993) 128-143 and in Potrykus *Annu. Rev. Plant Physiol. Plant Molec. Biol.* 42 (1991) 205-225). The nucleic acids or the construct to be expressed is preferably cloned into a vector which is suitable for transforming *Agrobacterium tumefaciens*, for example pBin19 (Bevan et al., *Nucl. Acids Res.* 12 (1984) 8711). *Agrobacteria* transformed by such a vector can then be used in known manner for the transformation of plants, in particular of crop plants such as by way of example tobacco plants, for example by bathing bruised leaves or chopped leaves in an *agrobacterial* solution and then culturing them in suitable media. The transformation of plants by means of *Agrobacterium tumefaciens* is described, for example, by Höfgen and Willmitzer in *Nucl. Acid Res.* (1988) 16, 9877 or is known inter alia from F.F. White, *Vectors for Gene Transfer in Higher Plants*; in *Transgenic Plants*, Vol. 1, Engineering and Utilization, eds. S.D. Kung and R. Wu, Academic Press, 1993, pp. 15-38.

**[0089]** *Agrobacteria* transformed by an expression vector according to the invention may likewise be used in known manner for the transformation of plants such as test plants like *Arabidopsis* or crop plants such as cereal crops, corn, oats, rye, barley, wheat, soybean, rice, cotton, sugar beet, canola, sunflower, flax, hemp, potatoes, tobacco, tomatoes, carrots, paprika, oilseed rape, tapioca, cassava, arrowroot, tagetes, alfalfa, lettuce and the various tree, nut and vine species, in particular of oil-containing crop plants such as soybean, peanut, castor oil plant, sunflower, com, cotton, flax, oilseed rape, coconut, oil palm, safflower (*Carthamus tinctorius*) or cocoa bean, e.g. by bathing bruised leaves or chopped leaves in an *agrobacterial* solution and then culturing them in suitable media. For the production of PUFAs, for example stearidonic acid, eicosapentaenoic acid and docosahexaenoic acid, borage, linseed, sunflower, safflower or Primulaceae are advantageously suitable. Other suitable organisms for the production of for example  $\gamma$ -linoleic acid, dihomogamma-linoleic acid or arachidonic acid are for example linseed, sunflower or safflower.

**[0090]** The genetically modified plant cells may be regenerated by all of the methods known to those skilled in the art. Appropriate methods can be found in the publications referred to above by S.D. Kung and R. Wu, Potrykus or Höfgen and Willmitzer.

**[0091]** Accordingly, a further aspect of the invention relates to transgenic organisms transformed by at least one nucleic acid sequence, expression cassette or vector according to the invention as well as cells, cell cultures, tissue, parts - such as, for example, leaves, roots, etc. in the case of plant organisms - or reproductive material derived from such organisms. The terms "host organism", "host cell", "recombinant (host) organism" and "transgenic (host) cell" are used here interchangeably. Of course these terms relate not only to the particular host organism or the particular target cell but also to the descendants or potential descendants of these organisms or cells. Since, due to mutation or environmental effects certain modifications may arise in successive generations, these descendants need not necessarily be identical with the parental cell but nevertheless are still encompassed by the term as used here.

**[0092]** For the purposes of the invention "transgenic" or "recombinant" means with regard for example to a nucleic acid sequence, an expression cassette (= gene construct, nucleic acid construct) or a vector containing the nucleic acid sequence according to the invention or an organism transformed by the nucleic acid sequences, expression cassette or vector according to the invention all those constructions produced by genetic engineering methods in which either

a) the nucleic acid sequence depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or

b) a genetic control sequence functionally linked to the nucleic acid sequence described under (a), for example a 3'- and/or 5'- genetic control sequence such as a promoter or terminator, or

c) (a) and (b)

are not found in their natural, genetic environment or have been modified by genetic engineering methods, wherein the modification may by way of example be a substitution, addition, deletion, inversion or insertion of one or more nucleotide residues. Natural genetic environment means the natural genomic or chromosomal locus in the organism of origin or inside the host organism or presence in a genomic library. In the case of a genomic library the natural genetic environment of the nucleic acid sequence is preferably retained at least in part. The environment borders the nucleic acid sequence at least on one side and has a sequence length of at least 50 bp, preferably at least 500 bp, particularly preferably at least 1,000 bp, most particularly preferably at least 5,000 bp. A naturally occurring expression cassette - for example the naturally occurring combination of the natural promoter of the nucleic acid sequence according to the invention with the corresponding  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene - turns into a transgenic expression cassette when the latter is modified by unnatural, synthetic ("artificial") methods such as by way of example a mutagenation. Appropriate methods are described by way of example in US 5,565,350 or WO 00/15815.

**[0093]** Suitable organisms or host organisms for the nucleic acid, expression cassette or vector according to the invention are advantageously in principle all organisms which are able to synthesize fatty acids, especially unsaturated fatty acids or are suitable for the expression of recombinant genes as described above. Further examples which may be mentioned are plants such as Arabidopsis, Asteraceae such as Calendula or crop plants such as soybean, peanut, castor oil plant, sunflower, corn, cotton, flax, oilseed rape, coconut, oil palm, safflower (*Carthamus tinctorius*) or cocoa bean. Preference is given to organisms which can naturally synthesize oils in relatively large quantities such as plants such as soybean, oilseed rape, coconut, oil palm, safflower, flax, castor oil plant, Calendula, peanut, cocoa bean or sunflower, and particular preference is given to soybean, flax, oilseed rape, sunflower or Calendula.

**[0094]** Further useful host cells are identified in: Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).

**[0095]** Usable expression strains, e.g. those exhibiting a relatively low protease activity, are described in: Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128.

**[0096]** A further object of the invention relates to the use of an expression cassette containing DNA sequences encoding a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase gene or DNA sequences hybridizing therewith for the transformation of plant cells, tissues or parts of plants. The aim of use is to increase the content of fatty acids, oils or lipids having an increased content of double bonds.

**[0097]** In doing so, depending on the choice of promoter, the  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase gene can be expressed specifically in the leaves, in the seeds, the nodules, in roots, in the stem or other parts of the plant. Those transgenic plants overproducing fatty acids, oils or lipids having at least three double bonds in the fatty acid molecule, the reproductive material thereof, together with the plant cells, tissues or parts thereof are a further object of the present invention.

**[0098]** The expression cassette or the nucleic acid sequences according to the invention containing a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase gene sequence can, moreover, also be employed for the transformation of the organisms identified by way of example above such as bacteria, cyanobacteria, yeasts, filamentous fungi, ciliates and algae with the objective of increasing the content of fatty acids, oils or lipids possessing at least three double bonds.

**[0099]** Within the framework of the present invention, increasing the content of fatty acids, oils or lipids possessing at least three double bonds means, for example, the artificially acquired trait of increased biosynthetic performance due to functional overexpression of the  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene in the organisms according to the invention, advantageously in the transgenic plants according to the invention, by comparison with the nongenetically modified initial plants at least for the duration of at least one plant generation.

**[0100]** The preferred locus of biosynthesis, of fatty acids, oils or lipids for example, is generally the seed or cell layers of the seed so that a seed-specific expression of the  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene is appropriate. It is, however, obvious that the biosynthesis of fatty acids, oils or lipids need not be limited to the seed tissue but rather can also occur in tissue-specific manner in all other parts of the plant - in epidermis cells or in the nodules for example.

**[0101]** A constitutive expression of the exogenous  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene is, moreover, advantageous. On the other hand, however, an inducible expression may also appear desirable.

**[0102]** The efficiency of the expression of the  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene can be determined, for example, *in vitro* by shoot meristem propagation. In addition, an expression of the  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase gene modified in nature and level and its effect on fatty acid, oil or lipid biosynthesis performance can be tested on test plants in greenhouse trials.

**[0103]** An additional object of the invention comprises transgenic plants transformed by an expression cassette containing a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase gene sequence according to the invention or DNA sequences hybridizing therewith, as well as transgenic cells, tissue, parts and reproduction material of such plants. Particular preference is given in this case to transgenic crop plants such as by way of example barley, wheat, rye, oats, corn, soybean, rice, cotton, sugar beet, oilseed rape and canola, sunflower, flax, hemp, thistle, potatoes, tobacco, tomatoes, tapioca, cassava, arrowroot, alfalfa, lettuce and the various tree, nut and vine species.

**[0104]** For the purposes of the invention plants are mono- and dicotyledonous plants, mosses or algae.

**[0105]** A further refinement according to the invention are transgenic plants as described above which contain a nucleic acid sequence according to the invention or a expression cassette according to the invention.

**[0106]** Also disclosed are:

- A method for the transformation of a plant comprising the introduction of expression cassettes according to the invention containing a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase gene sequence derived from algae such as *Euglenia* or *Isochrysis*, fungi such as *Mortierella* or mosses such as *Physcomitrella* or DNA' sequences hybridizing therewith into a plant cell, into callus tissue, an entire plant or protoplasts of plants.
- A method for producing PUFAs, wherein the method comprises the growing of a transgenic organism comprising

a nucleic acid as described herein or a vector encoding a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase which specifically synthesize poly unsaturated fatty acids with at least three double bonds in the fatty acid molecule

- Use of a  $\Delta$ -8-desaturase, a  $\Delta$ -9-elongase and/or a  $\Delta$ -5-desaturase DNA gene sequence or DNA sequences hybridizing therewith for the production of plants having an increased content of fatty acids, oils or lipids having at least three double bonds due to the expression of said  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase DNA sequence in plants.

**[0107]** Also disclosed is a method for producing unsaturated fatty acids comprising: introducing at least one said nucleic acid sequence described herein or at least one nucleic acid construct or vector containing said nucleic acid sequence into a preferably oil-producing organism such as a plant or a fungi; growing said organism; isolating oil contained in said organism; and liberating the fatty acids present in said oil. These unsaturated fatty acids advantageously contain at least three double bonds in the fatty acid molecule. The fatty acids may be liberated from the oils or lipids, for example by basic hydrolysis, e.g. using NaOH or KOH or by acid hydrolysis preferably in the presence of an alcohol such as methanol or ethanol. Said fatty acid liberation leads to free fatty acids or to the corresponding alkyl esters of the fatty acids. In principle an enzymatic hydrolysis for example with a lipase as enzyme is also possible. Starting from said free fatty acids or fatty acid alkyl esters mono-, di- and/or triglycerides can be synthesized either chemically or enzymatically. In another preferred embodiment of the inventive process the alkyl ester of the fatty acids are produced from the oils and lipids by transesterification with an enzyme of with conventional chemistry. A preferred method is the production of the alkyl ester in the presence of alcohols of the corresponding lower alcohols (C1 to C10 alcohols such as methanol, ethanol, propanol, butanol, hexanol etc.) such as methanolate or ethanolate. Therefore as the skilled worker knows the alcohol in the presence of a catalytic amount of a base such as NaOH or KOH is added to the oils or lipids.

**[0108]** A method for producing triglycerides having an increased content of unsaturated fatty acids comprising: introducing at least one said nucleic acid sequence according to the invention or at least one expression cassette according to the invention into an oil-producing organism; growing said organism; and isolating oil contained in said organism; is also numbered among the objects of the invention.

**[0109]** Also disclosed is a method for producing triglycerides having an increased content of unsaturated fatty acids advantageously having an increased content of unsaturated fatty acids is a method wherein the fatty acids are liberated from the triglycerides with the aid of basic hydrolysis known to those skilled in the art or by means of an enzyme such as a lipase.

**[0110]** The methods specified above advantageously allow the synthesis of fatty acids or triglycerides having an increased content of fatty acids containing at least three double bonds in the fatty acid molecule.

**[0111]** The methods identified above advantageously allow the synthesis of fatty acids or triglycerides having an increased content of fatty acids containing at least three double bonds, wherein the substrate used for the reaction of the  $\Delta$ -8-desaturase,  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase is preferably - linoleic acid ( $C_{20:2}^{\Delta 9,12}$ ) acid and/or  $\alpha$ -linolenic acid ( $C_{18:2}^{\Delta 9,12,15}$ ). In this way the method identified above advantageously allows in particular the synthesis of fatty acids derived from linoleic acid ( $C_{20:2}^{\Delta 9,12}$ ),  $\alpha$ -linolenic acid ( $C_{18:2}^{\Delta 9,12,15}$ ),  $\gamma$ -linoleic acid ( $C_{18:3}^{\Delta 6,9,12}$ ), stearidonic acid ( $C_{18:4}^{\Delta 6,9,12,15}$ ), dihomo- $\gamma$ -linoleic acid ( $C_{20:3}^{\Delta 8,11,14}$ ) or such as by way of example eicosapentaenoic acid and arachidonic acid.

**[0112]** Examples of organisms for the said methods as described above are plants such as Arabidopsis, Primulaceae, borage, barley, wheat, rye, oats, corn, soybean, rice, cotton, sugar beet, oilseed rape and canola, sunflower, flax, hemp, potatoes, tobacco, tomatoes, rape, tapioca, cassava, arrowroot, alfalfa, peanut, castor oil plant, coconut, oil palm, safflower (*Carthamus tinctorius*) or cocoa bean, algae or protozoa such as dinoflagellates like *Cryptocodinium*. Preference is given to organisms which can naturally synthesize oils in relatively large quantities such as plants such as soybean, oilseed rape, coconut, oil palm, safflower, castor oil plant, Calendula, peanut, cocoa bean or sunflower, and particular preference is given to soybean, oilseed rape, sunflower, flax, Primulaceae, borage or *Carthamus*.

**[0113]** Depending on the host organism, the organisms used in the methods are grown or cultured in the manner known to those skilled in the art. Microorganisms such as fungi or algae are usually grown in a liquid medium containing a carbon source, usually in the form of sugars, a nitrogen source, usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese or magnesium salts and optionally vitamins at temperatures of between 10 °C and 60 °C, preferably between 15 °C and 40 °C with exposure to gaseous oxygen. In doing so the pH of the nutrient liquid may be kept at a fixed value, that is during growth it is or is not regulated. Growth can ensue in batch mode, semibatch mode or continuously. Nutrients can be provided at the start of fermentation or be fed in semicontinuously or continuously.

**[0114]** After transformation plants are first of all regenerated as described above and then cultured or cultivated as normal.

**[0115]** After growth the lipids are isolated from the organisms in the usual way. For this purpose, after harvesting the organisms may first of all be digested or used directly. The lipids are advantageously extracted using suitable solvents



such as apolar solvents like hexane or ethanol, isopropanol or mixtures such as hexane/isopropanol, phenol/chloroform/isoamyl alcohol at temperatures of between 0 °C and 80 °C, preferably between 20 °C and 50 °C. The biomass is usually extracted with an excess of solvent, for example an excess of solvent to biomass of 1:4. The solvent is then removed, for example by distillation. Extraction can also be done using supercritical CO<sub>2</sub>. After extraction the remaining biomass may be removed, for example by filtration.

**[0116]** The crude oil isolated in this way can then be further purified, for example by removing cloudiness by treatment with polar solvents such as acetone or chloroform and then filtration or centrifugation. Further purification through columns is also possible.

**[0117]** In order to obtain the free acids from the triglycerides the latter are saponified in the usual way.

**[0118]** Also disclosed are unsaturated fatty acids and triglycerides having an increased content of unsaturated fatty acids produced by the methods identified above and use thereof for producing foods, animal feeds, cosmetics or pharmaceuticals. For this purpose the latter are added in customary quantities to the foods, the animal feed, the cosmetics or pharmaceuticals.

**[0119]** Said unsaturated fatty acids as well as triglycerides having an increased content of unsaturated fatty acids produced by the methods identified above are the result of the expression of the nucleic acids according to the invention in the various host organisms. This results overall in a modification of the composition of the compounds in the host cell containing unsaturated fatty acids by comparison with the original starting host cells which do not contain the nucleic acids. These modifications are more marked in host organisms, for example plant cells, which naturally do not contain the proteins or enzymes encoded by the nucleic acids than in host organisms which naturally do contain the proteins or enzymes encoded by the nucleic acids. This gives rise to host organisms containing oils, lipids, phospholipids, sphingolipids, glycolipids, triacylglycerols and/or free fatty acids having a higher content of PUFAs with at least three double bonds. For the purposes of the invention, by an increased content is meant that the host organisms contain at least 5 %, advantageously at least 10 %, preferably at least 20 %, particularly preferably at least 30 %, most particularly preferably at least 40 % more polyunsaturated fatty acids by comparison with the initial organism which does not contain the nucleic acids according to the invention. This is particularly the case for plants which do not naturally contain longer-chain polyunsaturated C<sub>20</sub> or C<sub>22</sub> fatty acids such as EPA or ARA. Due to the expression of the nucleic acids novel lipid compositions are produced by said means these being a further aspect of the invention.

**[0120]** The invention is explained in more detail by the following examples.

### Examples

#### Example 1: General cloning methods

**[0121]** The cloning methods, such as by way of example restriction cleavages, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transformation of *Escherichia coli* cells, culture of bacteria and sequence analysis of recombinant DNA, were carried out as described in Sambrook et al. (1989) (Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6).

#### Example 2: Sequence analysis of recombinant DNA

**[0122]** Sequencing of recombinant DNA molecules was done using a laser fluorescence DNA sequencer from the ABI company by the method of Sanger (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA74, 5463-5467). Fragments resulting from a polymerase chain reaction were sequenced and checked to prevent polymerase errors in the constructs to be expressed.

#### Example 3: Cloning of the $\Delta$ -8-desaturase from *Euglena gracilis* (= SEQ ID NO: 1)

**[0123]** As a template for PCR amplification, cDNA from *Euglena gracilis* Strain Z was used. The cDNA was synthesised from total RNA extracted from cultures of *E. gracilis* strain Z. Unique primers to the initiating methionine and the stop codon of the *Euglena*  $\Delta$ -8-desaturase were synthesized as shown, including restriction sites as detailed

Primer 1: EDELTA8BamF

ATGGATCCACCATGAAGTCAAAGCGCCAA

Primer 2: EDELTA8XhoR

ATCTCGAGTTATAGAGCCTTCCCCGC

PCR protocol

**[0124]**

## EP 1 576 166 B1

Addition temperature: 1 min at 45 °C  
Denaturing temperature: 1 min at 94 °C  
Elongation temperature: 2 min at 72 °C  
Number of cycles: 30

5

**[0125]** The PCR products were separated on an agarose gel and a 1270 bp fragment was isolated. The PCR fragment was cloned in the pGEM-T easy vector (Promega) and the insert was then sequenced. This revealed the presence of an open reading frame of 1266 base pairs, encoding a protein of 421 amino acid residues and a stop codon. The C-terminus of the cloned  $\Delta$ -8-desaturase has high homologies to the  $\Delta$ -8-desaturase published by Wallis and Browse (Archives of Biochem. and Biophysics, Vol. 365, No. 2, 1999) which is reported to be an enzyme of 422 residues; see also related sequence by these authors [GenBank AF139720/ AAD45877] which purports to relate to the same  $\Delta$ -8-desaturase but describes an open reading frame of 419 residues]. The deduced amino acid sequence the *Euglena*  $\Delta$ -8-desaturase described in this present invention differs from that previously described by heterogeneity at the N-terminus. In particular, the first 25 amino acid residues of LARS  $\Delta$ -8-desaturase is:

15

MKSKRQALP LTIDGTTYDVS AWWNF

**[0126]** Whereas the sequence described by Wallis & Browse is:

20

MKSKRQALS PLQLMEQTYDV SAWVN (as given in ABB 1999)

**[0127]** Or, alternatively

MKSKRQALSPLQLMEQTYDVVNFH (as given in GenBank AAD45877)

25

**[0128]** Said heterogeneity present at the N-terminus of the desaturase sequence is not resultant of the PCR amplification or primers. The distinctions are true differences between the proteins.

Example 4: Construction of transgenic plants expressing the *Isochrysis galbana* elongase component IgASE1

30

**[0129]** The cloning of IgASE1 cDNA is described in: Qi, B., Beaudoin, F., Fraser, T., Stobart, A. K., Napier, J.A. and Lazarus, C.M. Identification of a cDNA encoding a novel C18- $\Delta$ -9-polyunsaturated fatty acid-specific elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana*. FEBS Letters 510, 159-165 (2002). The cDNA was released from plasmid vector pCR2.1-TOPO by digestion with *KpnI*, and ligated into the *KpnI* site of the intermediate vector pBlueBac 4.5 (Invitrogen). Recombinant plasmids were screened for insert orientation with *EcoRI*. The insert was released from a selected plasmid with *PstI* plus *EcoRI* and ligated into binary vector plasmid pCB302-1 (Xiang *et al.*, 1999) that had been cut with the same enzymes. This placed the IgASE1 coding region under the control of the CaMV 35S promoter as a translational fusion with the transit peptide of the small subunit of Rubisco (Xiang *et al.*, 1999), with the intention of targeting the elongase component to chloroplasts when expressed in transgenic plants. This recombinant binary vector was designated pCB302-1ASE. To construct a similar vector with expression of the elongase component targeted to the microsomal membrane, the IgASE1 coding region was removed from the intermediate vector by digestion with *BamHI* plus *SpeI*, and ligated into the corresponding sites of pCB302-3 (Xiang *et al.*, 1999, in which the map of pCB302-3 is incorrect: the CaMV 35S promoter (plus omega sequence) and nos terminator regions are reversed with respect to MCS2). This recombinant binary vector was designated pCB302-3ASE.

35

40

Example 5: Plant expression of the elongase

45

**[0130]** Binary vectors were transferred to *Agrobacterium tumefaciens* strain GV3101 by electroporation; transformed colonies were selected on medium containing 50  $\mu$ g ml<sup>-1</sup> kanamycin. Selected colonies were grown to stationary phase at 28°C, then the cells were concentrated by centrifugation and resuspended in a dipping solution containing 5% sucrose, 0.03% Silwet-177 and 10 mM MgCl<sub>2</sub>.

50

**[0131]** Seeds of *Arabidopsis thaliana* ecotype Columbia 4 were germinated on one-half-strength Murashige and Skoog medium, and seedlings were transferred to compost in 15 cm flower pots. Plants were grown to flowering stage in a growth cabinet at 21°C, with a 23 light and 1 hour dark cycle. Plant transformation was carried out by the floral dipping method of Clough and Bent (1998, Floral dip: a simplified method for *Agrobacterium*-mediated transformation of *Arabidopsis thaliana*. Plant Journal 16, 735-743 (1998), essentially as follows:

55

**[0132]** For each construct two pots containing 16 plants were inverted in the dipping solutions containing transformed *A. tumefaciens* (described above). The plants were then covered with a plastic bag and left at room temperature in the dark overnight. The bag was then removed and the plants transferred to the growth cabinet. Dipping (with fresh *A. tumefaciens* solutions) was repeated after 5 days and the plants were allowed to set seed. Bulk seed from dipped

## EP 1 576 166 B1

plants (= T1 seed) was collected, and approximately 10000 seed sprinkled onto compost in a seed tray, and, after stratification at 4°C for 2 days, cultivated in the growth cabinet. When seedlings had reached the 2 to 4 true-leaf stage they were sprayed with Liberty herbicide (Aventis, 0.5g glufosinate-ammonium l<sup>-1</sup>), and spraying was repeated one week later. Twelve herbicide-resistant plants were selected and potted on for each line (chloroplast or cytoplasm targeted elongase component), and allowed to self fertilize. Samples of T2 seed collected from these plants were germinated on one-half-strength Murashige and Skoog medium containing Liberty (5 mg glufosinate-ammonium l<sup>-1</sup>). T3 seed collected from individual surviving plants was then again germinated on Liberty plates to screen for lines that had ceased segregating for herbicide resistance. Total fatty acids extracted from leaves of such lines were analysed and those with the greatest C20 content (CB12-4 with the chloroplast-targeted elongase component and CA1-9 with the cytoplasm-targeted elongase component) selected.

Example 6: Production of transgenic plants expressing the *Isochrysis galbana* elongase component IgASE1 and the *Euglena gracilis*  $\Delta$ 8 desaturase EUGD8

**[0133]** The  $\Delta$ -8-desaturase coding region was removed from the yeast expression vector pESC-Trp with *Bam*HI plus *Xho*I, ligated into the *Bam*HI and *Xho*I sites of pBlueBac 4.5 (Invitrogen) and transformed into *E. coli* strain Tam1. The insert was removed from a recombinant plasmid with *Bgl*II and *Bam*HI, ligated into the *Bam*HI site of pBECKS<sub>19</sub>.6 and transformed into *E. coli* strain Tam1. DNA minipreparations were made of the recombinant plasmids of 6 transformant colonies; these were digested with *Xho*I to determine the orientation of insertion of the desaturase coding region in the binary vector. One recombinant plasmid with the insert in the correct orientation for expression from the CaMV 35S promoter was transferred to *Agrobacterium tumefaciens* strain GV3101 by electroporation and a dipping solution prepared from a transformed colony as described above.

**[0134]** *Arabidopsis thaliana* lines CB12-4 and CA1-9 (see above) were subjected to floral dipping as described above. Approximately 2000 T1-seed from each line were spread on 15 cm petri dishes containing one-half-strength Murashige and Skoog (solid) medium supplemented with 50  $\mu$ g ml<sup>-1</sup> kanamycin and germinated in the growth cabinet. 12 kanamycin-resistant plants of the CA1-9 parental line and 3 plants of the CB12-4 parental line were transferred to potting compost and further cultivated in the growth room. Fatty acid analysis was conducted on a leaf taken from each of the T2 plants, which were allowed to mature and set seed.

### References

#### **[0135]**

McCormac, A.C., Elliott, M.C. and Chen, D-F.; pBECKS. A flexible series of binary vectors for *Agrobacterium*-mediated plant transformation. *Molecular Biotechnology* 8, 199-213 (1997).

Xiang, C., Han, P., Lutziger, I., Wang, K. and Oliver, D.J.; A mini binary vector series for plant transformation. *Plant Molecular Biology* 40, 711-717 (1999).

Example 7: Production of transgenic plants expressing the *Isochrysis galbana* elongase component IgASE1 and the *Euglena gracilis*  $\Delta$ 8 desaturase EUGD8 and a  $\Delta$ 5 desaturase

**[0136]** The  $\Delta$ 5 desaturase from *Phaeodactylum tricornutum* was cloned into the pGPTV plasmid (Becker, D. et al.; *Plant Mol. Biol.* 20 (1992), 1195-1197) harbouring a hygromycin resistance selectable marker gene. For seed-specific expression the USP promoter from *Vicia faba* was cloned 5'-prime to the ATG of the  $\Delta$ 5 desaturase.

**[0137]** The binary vector was transferred to *Agrobacterium tumefaciens* strain GV 3101 and transformed colonies were selected on medium containing 30  $\mu$ gml<sup>-1</sup> hygromycin. Selected *Agrobacteria* were used for the transformation (flower transformation) of *Arabidopsis* plants carrying the T-DNA insertions with the  $\Delta$ 9 elongase and the  $\Delta$ 5 desaturase.

**[0138]** *Arabidopsis thaliana* seedlings were germinated on Murashige and Skoog medium containing hygromycin and resistant plants were transferred to the greenhouse.

**[0139]** Seeds collected from individual plants were harvested and the total fatty acid profile was analyzed using GC methods.

Example 8: Cloning of expression plasmids for seed-specific expression in plants

**[0140]** pBin-USP is a derivative of the plasmid pBin19. pBin-USP was produced from pBin19 by inserting a USP promoter as an *Eco*RI-*Bam*HI fragment into pBin19 (Bevan et al. (1980) *Nucl. Acids Res.* 12, 8711). The polyadenylation signal is that of gene 3 of the T-DNA of the Ti plasmid pTiACH5 (Gielen et al., (1984) *EMBO J.* 3, 835), whereby

## EP 1 576 166 B1

nucleotides 11749-11939 were isolated as a PvuII-HindIII fragment and after addition of SphI linkers to the PvuII interface between the SphI-HindIII interface of the vector were cloned. The USP promoter corresponds to nucleotides 1-684 (gene bank accession number X56240), wherein a part of the nonencoding region of the USP gene is contained in the promoter. The promoter fragment running to 684 base pairs was amplified by standard methods by means of commercial T7 standard primer (Stratagene) and using a synthesized primer through a PCR reaction.

Primer sequence:

5'-GTCGACCCGCGGACTAGTGGGCCCTCTAGACCCGGGGGATCC  
GGATCTGCTGGCTATGAA-3'

**[0141]** The PCR fragment was cut again using EcoRI/SalI and inserted into the vector pBin19 with OCS terminator. The plasmid having the designation pBinUSP was obtained. The constructs were used for transforming *Arabidopsis thaliana*, oilseed rape, tobacco and linseed.

Example 9: Production of transgenic oil crops

**[0142]** Production of transgenic plants (modified in accordance with Moloney et al., 1992, Plant Cell Reports, 8:238-242)

**[0143]** To produce transgenic oilseed rape plants binary vectors in *Agrobacterium tumefaciens* C58C1:pGV2260 or *Escherichia coli* were used (Deblaere et al, 1984, Nucl. Acids. Res. 13, 4777-4788). For transforming oilseed rape plants (var. Drakkar, NPZ Norddeutsche Pflanzenzucht, Hohenlieth, Germany) a 1:50 dilution of an overnight culture of a positively transformed agrobacteria colony in Murashige-Skoog medium (Murashige and Skoog 1962 Physiol. Plant. 15, 473) containing 3 % of saccharose (3MS medium) was used. Petioles or hypocotyledons of freshly germinated sterile rape plants (approx. 1 cm<sup>2</sup> each) were incubated in a Petri dish with a 1:50 agrobacteria dilution for 5-10 minutes. This was followed by 3-day incubation in darkness at 25 °C on 3MS medium containing 0.8 % of Bacto-Agar. After three days, culturing was continued with 16 hours of light / 8 hours of darkness and in a weekly cycle on MS medium containing 500 mg/l of Claforan (sodium cefotaxime), 50 mg/l of kanamycin, 20 microM of benzylaminopurine (BAP) and 1.6 g/l of glucose. Growing shoots were transferred onto MS medium containing 2 % of saccharose, 250 mg/l of Claforan and 0.8 % of Bacto-Agar. If after three weeks no roots had formed 2-indolylbutyric acid was added to the medium as a growth hormone for rooting purposes.

**[0144]** Regenerated shoots were obtained on 2MS medium using kanamycin and Claforan, transferred into soil after rooting and after culturing grown for two weeks in a climate-controlled chamber, brought to blossom and after harvesting of ripe seed investigated for  $\Delta$ -8-desaturase expression by means of lipid analyses. Lines having increased contents of double bonds at the  $\Delta$ -8-position were identified. In the stably transformed transgenic lines functionally expressing the transgene it was found that there is an increased content of double bonds at the  $\Delta$ -8-position by comparison with untransformed control plants.

**[0145]** The same procedure was done to create plants with  $\Delta$ -9-elongase and/or  $\Delta$ -5-desaturase activity.

a) Transgenic flax plants

**[0146]** Transgenic flax plants may be produced, for example by the by the method Bell et al., 1999, In Vitro Cell. Dev. Biol.-Plant. 35(6):456-465, by means of particle bombardment. Agrobacteria-mediated transformations can be produced, for example, as described by Mlynarova et al. (1994), Plant Cell Report 13: 282-285.

Example 10: Lipid extraction from seed and leave material

**[0147]** Plant material (approx 200 mg) was first of all mechanically homogenized by means of triturators in order to render it more amenable to extraction.

**[0148]** The disrupted cell sediment was hydrolyzed with 1 M methanolic hydrochloric acid and 5 % dimethoxypropane for 1 h at 85 °C and the lipids were transmethylated. The resultant fatty acid methyl esters (FAMES) were extracted in hexane. The extracted FAMES were analyzed by gas-liquid chromatograph using a capillary column (Chrompack, WCOT fused silica, CP wax 52 CB, 25 m, 0.32 mm) and a temperature gradient of from 170 °C to 240 °C in 20 min and 5 min at 240 °C. The identity of the fatty acid methyl esters was confirmed by comparison with corresponding FAME standards (Sigma). The identity and the position of the double bond was further analyzed by means of GC-MS by suitable chemical derivatization of the FAME mixtures, e.g. to form 4,4-dimethoxyoxazoline derivatives (Christie, 1998).

**[0149]** Figure 1 shows the fatty acid profile (FAMES) of leaf tissue from wildtype *Arabidopsis thaliana* as a control. Figure 2 shows the fatty acid profile (FAMES) of leaf tissue from transgenic *Arabidopsis* expressing the *Isochrysis*  $\Delta$ -9-elongase (see example 4). This *Arabidopsis* line was subsequently re-transformed with the *Euglena*  $\Delta$ -8-desaturase.

## EP 1 576 166 B1

The fatty acid profile (FAMES) of said double transformed *Arabidopsis* line (Line IsoElo X Eu D8 des) is given in Figure 3.

**[0150]** Furthermore this double transformed *Arabidopsis* line (Line IsoElo X Eu D8 des) was subsequently re-transformed with the *Mortierella*  $\Delta 5$  desaturase (Mort  $\Delta 5$ ) gene. The fatty acid profile (FAMES) of said triple transformed *Arabidopsis* line (Line IsoElo X EU D8 des x Mort  $\Delta 5$ ) is given in Figure 4.

Example 11: GC profiles of *Arabidopsis* leaf fatty acid methyl esters from different transgenics

**[0151]** Figure 5 shows GC profiles of *Arabidopsis* leaf fatty acid methyl esters extracted from wild type (WT 5a), single transgenic plants expressing *Isochrysis galbana*  $\Delta 9$  elongase gene Ig ASE1 (5b), double transgenic plant expressing the Ig ASE1 and *Euglena*  $\Delta 8$  desaturase (EU  $\Delta 8$ ) genes (5c) and the triple transgenic plant expressing the Ig ASE1, Eu  $\Delta 8$  and the *Mortierella*  $\Delta 5$  desaturase (Mort  $\Delta 5$ ) genes (5d).

Table 1 shows the fatty acid composition of *Arabidopsis* plants prepared from wild type (Wt), single transgenic plant expressing the *Isochrysis galbana* IgASE1 elongase gene, double transgenic plants expressing the IgASE1 elongase gene and the *Euglena*  $\Delta 8$  desaturase gene and triple transgenic plants expressing the IgASE1, the *Euglena*  $\Delta 8$  and the *Mortierella*  $\Delta 5$  desaturase gene. Analysis is of leaf tissue from rosette stage *Arabidopsis* plants. Each value represents the average of 2 measurements.

| Fatty acid (mol% of total) | Plant source |                   |                                 |  |
|----------------------------|--------------|-------------------|---------------------------------|--|
|                            | Wt           | IgASE1 transgenic | IgASE1+Eu $\Delta 8$ transgenic | IgASE1+Eu $\Delta 8$ +Mort $\Delta 5$ transgenic |
| 16:0                       | 19.9         | 19.2              | 14.7                            | 14.2   |
| 16:1                       | 2.8          | 3.3               | 1.8                             | 2.3  |
| 16:3                       | 13.1         | 12.2              | 19.9                            | 15.4   |
| 18:0                       | 1.7          | 2.4               | 0.8                             | 1.5  |
| 18:1n-9                    | 1.7          | 5.1               | 1.6                             | 3.4  |
| 18:2n-6                    | 11.2         | 9.0               | 4.2                             | 6.6  |
| 18:3n-3                    | 50.1         | 31.0              | 36.0                            | 31.2   |
| 20:2n-6                    | -            | 7.9               | 0.9                             | 3.2  |
| 20:3, $\Delta 5,11,14$     | -            |                   |                                 | 1.5  |
| 20:3n-6                    | -            | -                 | 9.1                             | 1.5  |
| 20:4n-6 (ARA)              | -            | -                 |                                 | 6.6  |
| 20:3n-3                    | -            | 9.9               | 4.0                             | 4.8  |
| 20,4 $\Delta 5,11,14,17$   | -            | -                 | -                               | 1.6  |
| 20:4n-3                    | -            | -                 | 7.2                             | 2.9  |
| 20:5n-3 (EPA)              | -            | -                 | -                               | 3.3  |
| Total C20 PUFAs            | -            | 17.8              | 21.2                            | 22.2   |

**[0152]** All transgenes are under the control of the 35S-CaMV viral promoter. *Isochrysis*  $\Delta 9$  elongase (IgASE1) with SSU Rubisco transit sequence [T-DNA Basta-r] were retransformed with *Euglena*  $\Delta 8$ -desaturase<sup>mut175+313</sup> [T-DNA Kanamycin-r]. The double transformed line, which is homozygous for both Basta-r and Kanamycin-r, were transformed again with *Mortierella*  $\Delta 5$  desaturase (T-DNA Hygromycin-r). The resulting triple transformed line is homozygous for both Basta-r and Kanamycin-r, but heterozygous for Hygromycin-r.

### SEQUENCE LISTING

**[0153]**

<110> University of Bristol

EP 1 576 166 B1

<120> Novel method for the production of polyunsaturated fatty acids

<130> 2002\_791

5 <140> 2002\_271  
<141> 2202-12-18

<160> 10

10 <170> PatentIn Ver. 2.0

<210> 1

<211> 1266

<212> DNA

15 <213> Euglena gracilis

<220>

<221> CDS

<222> (1)..(1266)

20 <223> delta-8-desaturase

<400> 1

25 atg aag tca aag cgc caa gcg ctt ccc ctt aca att gat gga aca aca 48  
Met Lys Ser Lys Arg Gln Ala Leu Pro Leu Thr Ile Asp Gly Thr Thr  
1 5 10 15

30 tat gat gtg tct gcc tgg gtc aat ttc cac cct ggt ggt gcg gaa att 96  
Tyr Asp Val Ser Ala Trp Val Asn Phe His Pro Gly Gly Ala Glu Ile  
20 25 30

35 ata gag aat tac caa gga agg gat gcc act gat gcc ttc atg gtt atg 144

40

45

50

55

EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Ile | Glu | Asn | Tyr | Gln | Gly | Arg | Asp | Ala | Thr | Asp | Ala | Phe | Met | Val | Met |     |
|    |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |     |
| 5  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | cac | tct | caa | gaa | gcc | ttc | gac | aag | ctc | aag | cgc | atg | ccc | aaa | atc | aat | 192 |
|    | His | Ser | Gln | Glu | Ala | Phe | Asp | Lys | Leu | Lys | Arg | Met | Pro | Lys | Ile | Asn |     |
| 10 |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
|    | ccc | agt | tct | gag | ttg | cca | ccc | cag | gct | gca | gtg | aat | gaa | gct | caa | gag | 240 |
| 15 | Pro | Ser | Ser | Glu | Leu | Pro | Pro | Gln | Ala | Ala | Val | Asn | Glu | Ala | Gln | Glu |     |
|    |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     | 80  |     |
|    | gat | ttc | cgg | aag | ctc | cga | gaa | gag | ttg | atc | gca | act | ggc | atg | ttt | gat | 288 |
| 20 | Asp | Phe | Arg | Lys | Leu | Arg | Glu | Glu | Leu | Ile | Ala | Thr | Gly | Met | Phe | Asp |     |
|    |     |     |     |     | 85  |     |     |     |     |     | 90  |     |     |     | 95  |     |     |
| 25 | gcc | tcc | ccc | ctc | tgg | tac | tca | tac | aaa | atc | agc | acc | aca | ctg | ggc | ctt | 336 |
|    | Ala | Ser | Pro | Leu | Trp | Tyr | Ser | Tyr | Lys | Ile | Ser | Thr | Thr | Leu | Gly | Leu |     |
| 30 |     |     |     |     | 100 |     |     |     |     |     | 105 |     |     |     | 110 |     |     |
|    | gga | gtg | ctg | ggt | tat | ttc | ctg | atg | ggt | cag | tat | cag | atg | tat | ttc | att | 384 |
| 35 | Gly | Val | Leu | Gly | Tyr | Phe | Leu | Met | Val | Gln | Tyr | Gln | Met | Tyr | Phe | Ile |     |
|    |     |     | 115 |     |     |     |     |     |     | 120 |     |     |     |     | 125 |     |     |
| 40 | ggg | gca | gtg | ttg | ctt | ggg | atg | cac | tat | caa | cag | atg | ggc | tgg | ctt | tct | 432 |
|    | Gly | Ala | Val | Leu | Leu | Gly | Met | His | Tyr | Gln | Gln | Met | Gly | Trp | Leu | Ser |     |
|    |     |     | 130 |     |     |     |     |     |     |     |     |     |     | 140 |     |     |     |
| 45 | cat | gac | att | tgc | cac | cac | cag | act | ttc | aag | aac | cgg | aac | tgg | aac | aac | 480 |
|    | His | Asp | Ile | Cys | His | His | Gln | Thr | Phe | Lys | Asn | Arg | Asn | Trp | Asn | Asn |     |
| 50 |     |     | 145 |     |     |     | 150 |     |     |     |     | 155 |     |     |     | 160 |     |
|    | ctc | gtg | gga | ctg | gta | ttt | ggc | aat | ggt | ctg | caa | ggt | ttt | tcc | gtg | aca | 528 |
|    | Leu | Val | Gly | Leu | Val | Phe | Gly | Asn | Gly | Leu | Gln | Gly | Phe | Ser | Val | Thr |     |
| 55 |     |     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |

EP 1 576 166 B1

tgc tgg aag gac aga cac aat gca cat cat tcg gca acc aat gtt caa 576  
 Cys Trp Lys Asp Arg His Asn Ala His His Ser Ala Thr Asn Val Gln  
 5 180 185 190

ggg cac gac cct gat att gac aac ctc ccc ctc tta gcc tgg tct gag 624  
 Gly His Asp Pro Asp Ile Asp Asn Leu Pro Leu Leu Ala Trp Ser Glu  
 10 195 200 205

gat gac gtc aca cgg gcg tca ccg att tcc cgc aag ctc att cag ttc 672  
 Asp Asp Val Thr Arg Ala Ser Pro Ile Ser Arg Lys Leu Ile Gln Phe  
 15 210 215 220

cag cag tat tat ttc ttg gtc atc tgt atc ttg ttg cgg ttc att tgg 720  
 Gln Gln Tyr Tyr Phe Leu Val Ile Cys Ile Leu Leu Arg Phe Ile Trp  
 20 225 230 235 240

tgt ttc cag agc gtg ttg acc gtg cgc agt ctg aag gac aga gat aac 768  
 Cys Phe Gln Ser Val Leu Thr Val Arg Ser Leu Lys Asp Arg Asp Asn  
 25 245 250 255

caa ttc tat cgc tct cag tat aag aag gag gcc att ggc ctc gcc ctg 816  
 Gln Phe Tyr Arg Ser Gln Tyr Lys Lys Glu Ala Ile Gly Leu Ala Leu  
 30 260 265 270

cat tgg aca ttg aag gcc ctg ttc cac tta ttc ttt atg ccc agc atc 864  
 His Trp Thr Leu Lys Ala Leu Phe His Leu Phe Phe Met Pro Ser Ile  
 35 275 280 285

ctc aca tcg ctg ttg gta ttt ttc gtt tcg gag ctg gtt ggc ggc ttc 912  
 Leu Thr Ser Leu Leu Val Phe Phe Val Ser Glu Leu Val Gly Gly Phe  
 40 290 295 300

ggc att gcg atc gtg gtg ttc atg aac cac tac cca ctg gag aag atc 960  
 Gly Ile Ala Ile Val Val Phe Met Asn His Tyr Pro Leu Glu Lys Ile  
 45 305 310 315 320



EP 1 576 166 B1

|    |   |      |
|----|---|------|
|    | ggg gac tcg gtc tgg gat ggc cat gga ttc tcg gtt ggc cag atc cat | 1008 |
|    | Gly Asp Ser Val Trp Asp Gly His Gly Phe Ser Val Gly Gln Ile His |      |
| 5  | 325 330 335   |      |
|    | gag acc atg aac att cgg cga ggg att atc aca gat tgg ttt ttc gga | 1056 |
| 10 | Glu Thr Met Asn Ile Arg Arg Gly Ile Ile Thr Asp Trp Phe Phe Gly |      |
|    | 340 345 350   |      |
|    | ggc ttg aac tac cag atc gag cac cat ttg tgg ccg acc ctc cct cgc | 1104 |
| 15 | Gly Leu Asn Tyr Gln Ile Glu His His Leu Trp Pro Thr Leu Pro Arg |      |
|    | 355 360 365   |      |
| 20 |   |      |
|    | cac aac ctg aca gcg gtt agc tac cag gtg gaa cag ctg tgc cag aag | 1152 |
|    | His Asn Leu Thr Ala Val Ser Tyr Gln Val Glu Gln Leu Cys Gln Lys |      |
| 25 | 370 375 380   |      |
|    | cac aac ctg ccg tat cgg aac ccg ctg ccc cat gaa ggg ttg gtc atc | 1200 |
| 30 | His Asn Leu Pro Tyr Arg Asn Pro Leu Pro His Glu Gly Leu Val Ile |      |
|    | 385 390 395 400   |      |
|    | ctg ctg cgc tat ctg gcg gtg ttc gcc cgg atg gcg gag aag caa ccc | 1248 |
| 35 | Leu Leu Arg Tyr Leu Ala Val Phe Ala Arg Met Ala Glu Lys Gln Pro |      |
|    | 405 410 415   |      |
| 40 | gcg ggg aag gct cta taa   | 1266 |
|    | Ala Gly Lys Ala Leu   |      |
|    | 420   |      |
| 45 | <210> 2   |      |
|    | <211> 421   |      |
|    | <212> PRT   |      |
|    | <213> Euglena gracilis  |      |
| 50 | <400> 2   |      |
| 55 |   |      |

EP 1 576 166 B1

1                    5                    10                    15  
 Met Lys Ser Lys Arg Gln Ala Leu Pro Leu Thr Ile Asp Gly Thr Thr  
 5  
 Tyr Asp Val Ser Ala Trp Val Asn Phe His Pro Gly Gly Ala Glu Ile  
 20                    25                    30  
 10  
 Ile Glu Asn Tyr Gln Gly Arg Asp Ala Thr Asp Ala Phe Met Val Met  
 35                    40                    45  
 15  
 His Ser Gln Glu Ala Phe Asp Lys Leu Lys Arg Met Pro Lys Ile Asn  
 50                    55                    60  
 20  
 Pro Ser Ser Glu Leu Pro Pro Gln Ala Ala Val Asn Glu Ala Gln Glu  
 65                    70                    75                    80  
 25  
 Asp Phe Arg Lys Leu Arg Glu Glu Leu Ile Ala Thr Gly Met Phe Asp  
 85                    90                    95  
 30  
 Ala Ser Pro Leu Trp Tyr Ser Tyr Lys Ile Ser Thr Thr Leu Gly Leu  
 100                    105                    110  
 35  
 Gly Val Leu Gly Tyr Phe Leu Met Val Gln Tyr Gln Met Tyr Phe Ile  
 115                    120                    125  
 40  
 Gly Ala Val Leu Leu Gly Met His Tyr Gln Gln Met Gly Trp Leu Ser  
 130                    135                    140  
 45  
 His Asp Ile Cys His His Gln Thr Phe Lys Asn Arg Asn Trp Asn Asn  
 145                    150                    155                    160  
 50  
 Leu Val Gly Leu Val Phe Gly Asn Gly Leu Gln Gly Phe Ser Val Thr  
 165                    170                    175  
 55  
 Cys Trp Lys Asp Arg His Asn Ala His His Ser Ala Thr Asn Val Gln

EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|
|    |     | 180 |     | 185 |     | 190 |     |     |     |     |     |     |     |     |     |     |  |  |  |
| 5  | Gly | His | Asp | Pro | Asp | Ile | Asp | Asn | Leu | Pro | Leu | Leu | Ala | Trp | Ser | Glu |  |  |  |
|    |     | 195 |     | 200 |     | 205 |     |     |     |     |     |     |     |     |     |     |  |  |  |
| 10 | Asp | Asp | Val | Thr | Arg | Ala | Ser | Pro | Ile | Ser | Arg | Lys | Leu | Ile | Gln | Phe |  |  |  |
|    |     | 210 |     | 215 |     | 220 |     |     |     |     |     |     |     |     |     |     |  |  |  |
| 15 | Gln | Gln | Tyr | Tyr | Phe | Leu | Val | Ile | Cys | Ile | Leu | Leu | Arg | Phe | Ile | Trp |  |  |  |
|    |     | 225 |     | 230 |     | 235 |     |     |     |     |     |     |     |     |     | 240 |  |  |  |
| 20 | Cys | Phe | Gln | Ser | Val | Leu | Thr | Val | Arg | Ser | Leu | Lys | Asp | Arg | Asp | Asn |  |  |  |
|    |     |     |     | 245 |     | 250 |     |     |     |     |     |     |     |     | 255 |     |  |  |  |
| 25 | Gln | Phe | Tyr | Arg | Ser | Gln | Tyr | Lys | Lys | Glu | Ala | Ile | Gly | Leu | Ala | Leu |  |  |  |
|    |     |     |     | 260 |     | 265 |     |     |     |     |     |     |     | 270 |     |     |  |  |  |
| 30 | His | Trp | Thr | Leu | Lys | Ala | Leu | Phe | His | Leu | Phe | Phe | Met | Pro | Ser | Ile |  |  |  |
|    |     |     |     | 275 |     | 280 |     |     |     |     |     |     |     | 285 |     |     |  |  |  |
| 35 | Leu | Thr | Ser | Leu | Leu | Val | Phe | Phe | Val | Ser | Glu | Leu | Val | Gly | Gly | Phe |  |  |  |
|    |     |     |     | 290 |     | 295 |     |     |     |     |     |     |     | 300 |     |     |  |  |  |
| 40 | Gly | Ile | Ala | Ile | Val | Val | Phe | Met | Asn | His | Tyr | Pro | Leu | Glu | Lys | Ile |  |  |  |
|    |     |     |     | 305 |     | 310 |     |     |     |     |     |     |     | 315 |     | 320 |  |  |  |
| 45 | Gly | Asp | Ser | Val | Trp | Asp | Gly | His | Gly | Phe | Ser | Val | Gly | Gln | Ile | His |  |  |  |
|    |     |     |     | 325 |     | 330 |     |     |     |     |     |     |     | 335 |     |     |  |  |  |
| 50 | Glu | Thr | Met | Asn | Ile | Arg | Arg | Gly | Ile | Ile | Thr | Asp | Trp | Phe | Phe | Gly |  |  |  |
|    |     |     |     | 340 |     | 345 |     |     |     |     |     |     |     | 350 |     |     |  |  |  |
| 55 | Gly | Leu | Asn | Tyr | Gln | Ile | Glu | His | His | Leu | Trp | Pro | Thr | Leu | Pro | Arg |  |  |  |
|    |     |     |     | 355 |     | 360 |     |     |     |     |     |     |     | 365 |     |     |  |  |  |

EP 1 576 166 B1

His Asn Leu Thr Ala Val Ser Tyr Gln Val Glu Gln Leu Cys Gln Lys  
 370 375 380

5

His Asn Leu Pro Tyr Arg Asn Pro Leu Pro His Glu Gly Leu Val Ile  
 385 390 395 400

10

Leu Leu Arg Tyr Leu Ala Val Phe Ala Arg Met Ala Glu Lys Gln Pro  
 405 410 415

15

Ala Gly Lys Ala Leu  
 420

20

<210> 3  
 <211> 777  
 <212> DNA  
 <213> Isochrysis galbana

25

<220>  
 <221> CDS  
 <222> (1)..(777)  
 <223> delta-9-elongase

30

<400> 3

atg gcc ctc gca aac gac gcg gga gag cgc atc tgg gcg gct gtg acc 48

35

Met Ala Leu Ala Asn Asp Ala Gly Glu Arg Ile Trp Ala Ala Val Thr  
 1 5 10 15

gac ccg gaa atc ctc att ggc acc ttc tcg tac ttg cta ctc aaa ccg 96

40

Asp Pro Glu Ile Leu Ile Gly Thr Phe Ser Tyr Leu Leu Leu Lys Pro  
 20 25 30

45

ctg ctc cgc aat tcc ggg ctg gtg gat gag aag aag ggc gca tac agg 144

50

Leu Leu Arg Asn Ser Gly Leu Val Asp Glu Lys Lys Gly Ala Tyr Arg  
 35 40 45

55

EP 1 576 166 B1

acg tcc atg atc tgg tac aac gtt ctg ctg gcg ctc ttc tct gcg ctg 192  
 Thr Ser Met Ile Trp Tyr Asn Val Leu Leu Ala Leu Phe Ser Ala Leu  
 5           50                   55                   60

agc ttc tac gtg acg gcg acc gcc ctc ggc tgg gac tat ggt acg ggc 240  
 10 Ser Phe Tyr Val Thr Ala Thr Ala Leu Gly Trp Asp Tyr Gly Thr Gly  
      65                   70                   75                   80

gcg tgg ctg cgc agg caa acc gcc gac aca ccg cag ccg ctc ttc cag 288  
 15 Ala Trp Leu Arg Arg Gln Thr Gly Asp Thr Pro Gln Pro Leu Phe Gln  
                  85                   90                   95

tgc ccg tcc ccg gtt tgg gac tcg aag ctc ttc aca tgg acc gcc aag 336  
 20 Cys Pro Ser Pro Val Trp Asp Ser Lys Leu Phe Thr Trp Thr Ala Lys  
                  100                   105                   110

gca ttc tat tac tcc aag tac gtg gag tac ctc gac acg gcc tgg ctg 384  
 30 Ala Phe Tyr Tyr Ser Lys Tyr Val Glu Tyr Leu Asp Thr Ala Trp Leu  
                  115                   120                   125

agg gtc tcc ttt ctc cag gcc ttc cac cac ttt ggc gcg ccg tgg gat 432  
 35 Arg Val Ser Phe Leu Gln Ala Phe His His Phe Gly Ala Pro Trp Asp  
      130                   135                   140

gtg tac ctc gcc att cgg ctg cac aac gag ggc gta tgg atc ttc atg 480  
 40 Val Tyr Leu Gly Ile Arg Leu His Asn Glu Gly Val Trp Ile Phe Met  
   145                   150                   155                   160

ttt ttc aac tcg ttc att cac acc atc atg tac acc tac tac gcc ctc 528  
 45 Phe Phe Asn Ser Phe Ile His Thr Ile Met Tyr Thr Tyr Tyr Gly Leu  
                  165                   170                   175

acc gcc gcc ggg tat aag ttc aag gcc aag ccg ctc atc acc gcg atg 576  
 55 Thr Ala Ala Gly Tyr Lys Phe Lys Ala Lys Pro Leu Ile Thr Ala Met

EP 1 576 166 B1

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | 180   | 185 | 190 |     |
| 5  | cag atc tgc cag ttc gtg ggc ggc ttc ctg ttg gtc tgg gac tac atc |     |     | 624 |
|    | Gln Ile Cys Gln Phe Val Gly Gly Phe Leu Leu Val Trp Asp Tyr Ile |     |     |     |
|    | 195   | 200 | 205 |     |
| 10 | aac gtc ccc tgc ttc aac tcg gac aaa ggg aag ttg ttc agc tgg gct |     |     | 672 |
|    | Asn Val Pro Cys Phe Asn Ser Asp Lys Gly Lys Leu Phe Ser Trp Ala |     |     |     |
| 15 | 210   | 215 | 220 |     |
| 20 | ttc aac tat gca tac gtc ggc tcg gtc ttc ttg ctc ttc tgc cac ttt |     |     | 720 |
|    | Phe Asn Tyr Ala Tyr Val Gly Ser Val Phe Leu Leu Phe Cys His Phe |     |     |     |
|    | 225   | 230 | 235 | 240 |
| 25 | ttc tac cag gac aac ttg gca acg aag aaa tcg gcc aag gcg ggc aag |     |     | 768 |
|    | Phe Tyr Gln Asp Asn Leu Ala Thr Lys Lys Ser Ala Lys Ala Gly Lys |     |     |     |
|    |   | 245 | 250 | 255 |
| 30 | cag ctc tag   |     |     | 777 |
|    | Gln Leu   |     |     |     |
| 35 | <210> 4   |     |     |     |
|    | <211> 258   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Isochrysis galbana  |     |     |     |
| 40 | <400> 4   |     |     |     |
|    | Met Ala Leu Ala Asn Asp Ala Gly Glu Arg Ile Trp Ala Ala Val Thr |     |     |     |
|    | 1   | 5   | 10  | 15  |
| 45 | Asp Pro Glu Ile Leu Ile Gly Thr Phe Ser Tyr Leu Leu Leu Lys Pro |     |     |     |
|    | 20  | 25  | 30  |     |
| 50 | Leu Leu Arg Asn Ser Gly Leu Val Asp Glu Lys Lys Gly Ala Tyr Arg |     |     |     |
| 55 |   |     |     |     |

EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    |     | 35  |     |     |     |     |     | 40  |     |     |     |     |     | 45  |     |     |  |
| 5  | Thr | Ser | Met | Ile | Trp | Tyr | Asn | Val | Leu | Leu | Ala | Leu | Phe | Ser | Ala | Leu |  |
|    |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |
| 10 | Ser | Phe | Tyr | Val | Thr | Ala | Thr | Ala | Leu | Gly | Trp | Asp | Tyr | Gly | Thr | Gly |  |
|    | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |  |
| 15 | Ala | Trp | Leu | Arg | Arg | Gln | Thr | Gly | Asp | Thr | Pro | Gln | Pro | Leu | Phe | Gln |  |
|    |     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |  |
| 20 | Cys | Pro | Ser | Pro | Val | Trp | Asp | Ser | Lys | Leu | Phe | Thr | Trp | Thr | Ala | Lys |  |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     |     | 110 |     |  |
| 25 | Ala | Phe | Tyr | Tyr | Ser | Lys | Tyr | Val | Glu | Tyr | Leu | Asp | Thr | Ala | Trp | Leu |  |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
| 30 | Arg | Val | Ser | Phe | Leu | Gln | Ala | Phe | His | His | Phe | Gly | Ala | Pro | Trp | Asp |  |
|    | 130 |     |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |
| 35 | Val | Tyr | Leu | Gly | Ile | Arg | Leu | His | Asn | Glu | Gly | Val | Trp | Ile | Phe | Met |  |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |
| 40 | Phe | Phe | Asn | Ser | Phe | Ile | His | Thr | Ile | Met | Tyr | Thr | Tyr | Tyr | Gly | Leu |  |
|    |     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |  |
| 45 | Thr | Ala | Ala | Gly | Tyr | Lys | Phe | Lys | Ala | Lys | Pro | Leu | Ile | Thr | Ala | Met |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |
| 50 | Gln | Ile | Cys | Gln | Phe | Val | Gly | Gly | Phe | Leu | Leu | Val | Trp | Asp | Tyr | Ile |  |
|    |     |     | 195 |     |     |     |     | 200 |     |     |     |     |     | 205 |     |     |  |
| 55 | Asn | Val | Pro | Cys | Phe | Asn | Ser | Asp | Lys | Gly | Lys | Leu | Phe | Ser | Trp | Ala |  |
|    | 210 |     |     |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     |  |

EP 1 576 166 B1

Phe Asn Tyr Ala Tyr Val Gly Ser Val Phe Leu Leu Phe Cys His Phe  
 225 230 235 240

5

Phe Tyr Gln Asp Asn Leu Ala Thr Lys Lys Ser Ala Lys Ala Gly Lys  
 245 250 255

10

Gln Leu

<210> 5  
 <211> 1410  
 <212> DNA  
 <213> Phaeodactylum tricorutum

15

<220>  
 <221> CDS  
 <222> (1)..(1410)  
 <223> delta-5-desaturase

20

<400> 5

25

atg gct ccg gat gcg gat aag ctt cga caa cgc cag acg act gcg gta 48

Met Ala Pro Asp Ala Asp Lys Leu Arg Gln Arg Gln Thr Thr Ala Val  
 1 5 10 15

30

gcg aag cac aat gct gct acc ata tcg acg cag gaa cgc ctt tgc agt 96

Ala Lys His Asn Ala Ala Thr Ile Ser Thr Gln Glu Arg Leu Cys Ser  
 20 25 30

35

ctg tct tcg ctc aaa ggc gaa gaa gtc tgc atc gac gga atc atc tat 144

Leu Ser Ser Leu Lys Gly Glu Glu Val Cys Ile Asp Gly Ile Ile Tyr  
 35 40 45

40

gac ctc caa tca ttc gat cat ccc ggg ggt gaa acg atc aaa atg ttt 192

Asp Leu Gln Ser Phe Asp His Pro Gly Gly Glu Thr Ile Lys Met Phe  
 50 55 60

45

50

55



EP 1 576 166 B1

ggt ggc aac gat gtc act gta cag tac aag atg att cac ccg tac cat 240  
 Gly Gly Asn Asp Val Thr Val Gln Tyr Lys Met Ile His Pro Tyr His  
 5           65                           70                           75                           80

acc gag aag cat ttg gaa aag atg aag cgt gtc ggc aag gtg acg gat 288  
 Thr Glu Lys His Leu Glu Lys Met Lys Arg Val Gly Lys Val Thr Asp  
 10                                       85                                       90                                       95

ttc gtc tgc gag tac aag ttc gat acc gaa ttt gaa cgc gaa atc aaa 336  
 Phe Val Cys Glu Tyr Lys Phe Asp Thr Glu Phe Glu Arg Glu Ile Lys  
 15                                       100                                       105                                       110

cga gaa gtc ttc aag att gtg cga cga ggc aag gat ttc ggt act ttg 384  
 Arg Glu Val Phe Lys Ile Val Arg Arg Gly Lys Asp Phe Gly Thr Leu  
 20                                       115                                       120                                       125

gga tgg ttc ttc cgt gcg ttt tgc tac att gcc att ttc ttc tac ctg 432  
 Gly Trp Phe Phe Arg Ala Phe Cys Tyr Ile Ala Ile Phe Phe Tyr Leu  
 25                                       130                                       135                                       140

cag tac cat tgg gtc acc acg gga acc tct tgg ctg ctg gcc gtg gcc 480  
 Gln Tyr His Trp Val Thr Thr Gly Thr Ser Trp Leu Leu Ala Val Ala  
 30                                       145                                       150                                       155                                       160

tac gga atc tcc caa gcg atg att ggc atg aat gtc cag cac gat gcc 528  
 Tyr Gly Ile Ser Gln Ala Met Ile Gly Met Asn Val Gln His Asp Ala  
 35                                       165                                       170                                       175

aac cac ggg gcc acc tcc aag cgt ccc tgg gtc aac gac atg cta ggc 576  
 Asn His Gly Ala Thr Ser Lys Arg Pro Trp Val Asn Asp Met Leu Gly  
 40                                       180                                       185                                       190

ctc ggt gcg gat ttt att ggt ggt tcc aag tgg ctc tgg cag gaa caa 624  
 Leu Gly Ala Asp Phe Ile Gly Gly Ser Lys Trp Leu Trp Gln Glu Gln  
 45                                       195                                       200

EP 1 576 166 B1

|    |   |  |     |  |     |      |
|----|---|--|-----|--|-----|------|
|    | 195   |  | 200 |  | 205 |      |
| 5  | cac tgg acc cac cac gct tac acc aat cac gcc gag atg gat ccc gat |  |     |  |     | 672  |
|    | His Trp Thr His His Ala Tyr Thr Asn His Ala Glu Met Asp Pro Asp |  |     |  |     |      |
|    | 210   |  | 215 |  | 220 |      |
| 10 | agc ttt ggt gcc gaa cca atg ctc cta ttc aac gac tat ccc ttg gat |  |     |  |     | 720  |
|    | Ser Phe Gly Ala Glu Pro Met Leu Leu Phe Asn Asp Tyr Pro Leu Asp |  |     |  |     |      |
|    | 225   |  | 230 |  | 235 | 240  |
| 15 | cat ccc gct cgt acc tgg cta cat cgc ttt caa gca ttc ttt tac atg |  |     |  |     | 768  |
|    | His Pro Ala Arg Thr Trp Leu His Arg Phe Gln Ala Phe Phe Tyr Met |  |     |  |     |      |
| 20 |   |  | 245 |  | 250 | 255  |
| 25 | ccc gtc ttg gct gga tac tgg ttg tcc gct gtc ttc aat cca caa att |  |     |  |     | 816  |
|    | Pro Val Leu Ala Gly Tyr Trp Leu Ser Ala Val Phe Asn Pro Gln Ile |  |     |  |     |      |
|    |   |  | 260 |  | 265 | 270  |
| 30 | ctt gac ctc cag caa cgc ggc gca ctt tcc gtc ggt atc cgt ctc gac |  |     |  |     | 864  |
|    | Leu Asp Leu Gln Gln Arg Gly Ala Leu Ser Val Gly Ile Arg Leu Asp |  |     |  |     |      |
|    | 275   |  | 280 |  | 285 |      |
| 35 | aac gct ttc att cac tcg cga cgc aag tat gcg gtt ttc tgg cgg gct |  |     |  |     | 912  |
|    | Asn Ala Phe Ile His Ser Arg Arg Lys Tyr Ala Val Phe Trp Arg Ala |  |     |  |     |      |
| 40 | 290   |  | 295 |  | 300 |      |
| 45 | gtg tac att gcg gtg aac gtg att gct ccg ttt tac aca aac tcc ggc |  |     |  |     | 960  |
|    | Val Tyr Ile Ala Val Asn Val Ile Ala Pro Phe Tyr Thr Asn Ser Gly |  |     |  |     |      |
|    | 305   |  | 310 |  | 315 | 320  |
| 50 | ctc gaa tgg tcc tgg cgt gtc ttt gga aac atc atg ctc atg ggt gtg |  |     |  |     | 1008 |
|    | Leu Glu Trp Ser Trp Arg Val Phe Gly Asn Ile Met Leu Met Gly Val |  |     |  |     |      |
|    |   |  | 325 |  | 330 | 335  |
| 55 | gcg gaa tcg ctc gcg ctg gcg gtc ctg ttt tcg ttg tcg cac aat ttc |  |     |  |     | 1056 |

EP 1 576 166 B1

Ala Glu Ser Leu Ala Leu Ala Val Leu Phe Ser Leu Ser His Asn Phe  
 340 345 350

5  
 gaa tcc gcg gat cgc gat ccg acc gcc cca ctg aaa aag acg gga gaa 1104  
 Glu Ser Ala Asp Arg Asp Pro Thr Ala Pro Leu Lys Lys Thr Gly Glu  
 10 355 360 365

cca gtc gac tgg ttc aag aca cag gtc gaa act tcc tgc act tac ggt 1152  
 15 Pro Val Asp Trp Phe Lys Thr Gln Val Glu Thr Ser Cys Thr Tyr Gly  
 370 375 380

gga ttc ctt tcc ggt tgc ttc acg gga ggt ctc aac ttt cag gtt gaa 1200  
 20 Gly Phe Leu Ser Gly Cys Phe Thr Gly Gly Leu Asn Phe Gln Val Glu  
 385 390 395 400

cac cac ttg ttc cca cgc atg agc agc gct tgg tat ccc tac att gcc 1248  
 25 His His Leu Phe Pro Arg Met Ser Ser Ala Trp Tyr Pro Tyr Ile Ala  
 405 410 415

ccc aag gtc cgc gaa att tgc gcc aaa cac gcc gtc cac tac gcc tac 1296  
 35 Pro Lys Val Arg Glu Ile Cys Ala Lys His Gly Val His Tyr Ala Tyr  
 420 425 430

tac ccg tgg atc cac caa aac ttt ctc tcc acc gtc cgc tac atg cac 1344  
 40 Tyr Pro Trp Ile His Gln Asn Phe Leu Ser Thr Val Arg Tyr Met His  
 435 440 445

gcg gcc ggg acc ggt gcc aac tgg cgc cag atg gcc aga gaa aat ccc 1392  
 45 Ala Ala Gly Thr Gly Ala Asn Trp Arg Gln Met Ala Arg Glu Asn Pro  
 450 455 460

50  
 ttg acc gga cgg gcg taa 1410  
 Leu Thr Gly Arg Ala  
 55 465 470

<210> 6  
 <211> 469

EP 1 576 166 B1

<212> PRT

<213> Phaeodactylum tricornutum

<400> 6

5  
 Met Ala Pro Asp Ala Asp Lys Leu Arg Gln Arg Gln Thr Thr Ala Val  
 1 5 10 15

10  
 Ala Lys His Asn Ala Ala Thr Ile Ser Thr Gln Glu Arg Leu Cys Ser  
 20 25 30

15  
 Leu Ser Ser Leu Lys Gly Glu Glu Val Cys Ile Asp Gly Ile Ile Tyr  
 35 40 45

20  
 Asp Leu Gln Ser Phe Asp His Pro Gly Gly Glu Thr Ile Lys Met Phe  
 50 55 60

25  
 Gly Gly Asn Asp Val Thr Val Gln Tyr Lys Met Ile His Pro Tyr His  
 65 70 75 80

30  
 Thr Glu Lys His Leu Glu Lys Met Lys Arg Val Gly Lys Val Thr Asp  
 85 90 95

35  
 Phe Val Cys Glu Tyr Lys Phe Asp Thr Glu Phe Glu Arg Glu Ile Lys  
 100 105 110

40  
 Arg Glu Val Phe Lys Ile Val Arg Arg Gly Lys Asp Phe Gly Thr Leu  
 115 120 125

45  
 Gly Trp Phe Phe Arg Ala Phe Cys Tyr Ile Ala Ile Phe Phe Tyr Leu  
 130 135 140

50  
 Gln Tyr His Trp Val Thr Thr Gly Thr Ser Trp Leu Leu Ala Val Ala

55

EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | 145 |     | 150 |     | 155 |     | 160 |     |     |     |     |     |     |     |     |     |
| 5  | Tyr | Gly | Ile | Ser | Gln | Ala | Met | Ile | Gly | Met | Asn | Val | Gln | His | Asp | Ala |
|    |     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| 10 | Asn | His | Gly | Ala | Thr | Ser | Lys | Arg | Pro | Trp | Val | Asn | Asp | Met | Leu | Gly |
|    |     |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |
| 15 | Leu | Gly | Ala | Asp | Phe | Ile | Gly | Gly | Ser | Lys | Trp | Leu | Trp | Gln | Glu | Gln |
|    |     |     |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |
| 20 | His | Trp | Thr | His | His | Ala | Tyr | Thr | Asn | His | Ala | Glu | Met | Asp | Pro | Asp |
|    |     |     |     |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |
| 25 | Ser | Phe | Gly | Ala | Glu | Pro | Met | Leu | Leu | Phe | Asn | Asp | Tyr | Pro | Leu | Asp |
|    |     |     |     |     | 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |
| 30 | His | Pro | Ala | Arg | Thr | Trp | Leu | His | Arg | Phe | Gln | Ala | Phe | Phe | Tyr | Met |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| 35 | Pro | Val | Leu | Ala | Gly | Tyr | Trp | Leu | Ser | Ala | Val | Phe | Asn | Pro | Gln | Ile |
|    |     |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |
| 40 | Leu | Asp | Leu | Gln | Gln | Arg | Gly | Ala | Leu | Ser | Val | Gly | Ile | Arg | Leu | Asp |
|    |     |     |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |
| 45 | Asn | Ala | Phe | Ile | His | Ser | Arg | Arg | Lys | Tyr | Ala | Val | Phe | Trp | Arg | Ala |
|    |     |     |     |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |
| 50 | Val | Tyr | Ile | Ala | Val | Asn | Val | Ile | Ala | Pro | Phe | Tyr | Thr | Asn | Ser | Gly |
|    |     |     |     |     | 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |
| 55 | Leu | Glu | Trp | Ser | Trp | Arg | Val | Phe | Gly | Asn | Ile | Met | Leu | Met | Gly | Val |
|    |     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |

EP 1 576 166 B1

Ala Glu Ser Leu Ala Leu Ala Val Leu Phe Ser Leu Ser His Asn Phe  
 340 345 350

5

Glu Ser Ala Asp Arg Asp Pro Thr Ala Pro Leu Lys Lys Thr Gly Glu  
 355 360 365

10

Pro Val Asp Trp Phe Lys Thr Gln Val Glu Thr Ser Cys Thr Tyr Gly  
 370 375 380

15

Gly Phe Leu Ser Gly Cys Phe Thr Gly Gly Leu Asn Phe Gln Val Glu  
 385 390 395 400

20

His His Leu Phe Pro Arg Met Ser Ser Ala Trp Tyr Pro Tyr Ile Ala  
 405 410 415

25

Pro Lys Val Arg Glu Ile Cys Ala Lys His Gly Val His Tyr Ala Tyr  
 420 425 430

30

Tyr Pro Trp Ile His Gln Asn Phe Leu Ser Thr Val Arg Tyr Met His  
 435 440 445

35

Ala Ala Gly Thr Gly Ala Asn Trp Arg Gln Met Ala Arg Glu Asn Pro  
 450 455 460

40

Leu Thr Gly Arg Ala  
 465

45

<210> 7  
 <211> 1344  
 <212> DNA  
 <213> Ceratodon purpureus

50

<220>  
 <221> CDS  
 <222> (1)..(1344)  
 <223> delta-5-desaturase

55

<400> 7

EP 1 576 166 B1

atg gta tta cga gag caa gag cat gag cca ttc ttc att aaa att gat 48  
 Met Val Leu Arg Glu Gln Glu His Glu Pro Phe Phe Ile Lys Ile Asp  
 5           1                   5                   10                   15

gga aaa tgg tgt caa att gac gat gct gtc ctg aga tca cat cca ggt 96  
 Gly Lys Trp Cys Gln Ile Asp Asp Ala Val Leu Arg Ser His Pro Gly  
 10                   20                   25                   30

ggt agt gca att act acc tat aaa aat atg gat gcc act acc gta ttc 144  
 Gly Ser Ala Ile Thr Thr Tyr Lys Asn Met Asp Ala Thr Thr Val Phe  
 15                   35                   40                   45

cac aca ttc cat act ggt tct aaa gaa gcg tat caa tgg ctg aca gaa 192  
 His Thr Phe His Thr Gly Ser Lys Glu Ala Tyr Gln Trp Leu Thr Glu  
 20                   50                   55                   60

ttg aaa aaa gag tgc cct aca caa gaa cca gag atc cca gat att aag 240  
 Leu Lys Lys Glu Cys Pro Thr Gln Glu Pro Glu Ile Pro Asp Ile Lys  
 30                   65                   70                   75                   80

gat gac cca atc aaa gga att gat gat gtg aac atg gga act ttc aat 288  
 Asp Asp Pro Ile Lys Gly Ile Asp Asp Val Asn Met Gly Thr Phe Asn  
 35                   85                   90                   95

att tct gag aaa cga tct gcc caa ata aat aaa agt ttc act gat cta 336  
 Ile Ser Glu Lys Arg Ser Ala Gln Ile Asn Lys Ser Phe Thr Asp Leu  
 40                   100                   105                   110

cgt atg cga gtt cgt gca gaa gga ctt atg gat gga tct cct ttg ttc 384  
 Arg Met Arg Val Arg Ala Glu Gly Leu Met Asp Gly Ser Pro Leu Phe  
 50                   115                   120                   125

55

EP 1 576 166 B1

|    |   |     |
|----|---|-----|
|    | tac att aga aaa att ctt gaa aca atc ttc aca att ctt ttt gca ttc | 432 |
|    | Tyr Ile Arg Lys Ile Leu Glu Thr Ile Phe Thr Ile Leu Phe Ala Phe |     |
| 5  | 130 135 140   |     |
|    | tac ctt caa tac cac aca tat tat ctt cca tca gct att cta atg gga | 480 |
| 10 | Tyr Leu Gln Tyr His Thr Tyr Tyr Leu Pro Ser Ala Ile Leu Met Gly |     |
|    | 145 150 155 160   |     |
|    | gtt gcg tgg caa caa ttg gga tgg tta atc cat gaa ttc gca cat cat | 528 |
| 15 | Val Ala Trp Gln Gln Leu Gly Trp Leu Ile His Glu Phe Ala His His |     |
|    | 165 170 175   |     |
| 20 | cag ttg ttc aaa aac aga tac tac aat gat ttg gcc agc tat ttc gtt | 576 |
|    | Gln Leu Phe Lys Asn Arg Tyr Tyr Asn Asp Leu Ala Ser Tyr Phe Val |     |
| 25 | 180 185 190   |     |
|    | gga aac ttt tta caa gga ttc tca tct ggt ggt tgg aaa gag cag cac | 624 |
| 30 | Gly Asn Phe Leu Gln Gly Phe Ser Ser Gly Gly Trp Lys Glu Gln His |     |
|    | 195 200 205   |     |
|    | aat gtg cat cac gca gcc aca aat gtt gtt gga cga gac gga gat ctt | 672 |
| 35 | Asn Val His His Ala Ala Thr Asn Val Val Gly Arg Asp Gly Asp Leu |     |
|    | 210 215 220   |     |
| 40 | gat tta gtc cca ttc tat gct aca gtg gca gaa cat ctc aac aat tat | 720 |
|    | Asp Leu Val Pro Phe Tyr Ala Thr Val Ala Glu His Leu Asn Asn Tyr |     |
|    | 225 230 235 240   |     |
| 45 | tct cag gat tca tgg gtt atg act cta ttc aga tgg caa cat gtt cat | 768 |
|    | Ser Gln Asp Ser Trp Val Met Thr Leu Phe Arg Trp Gln His Val His |     |
| 50 | 245 250 255   |     |
|    | tgg aca ttc atg tta cca ttc ctc cgt ctc tcg tgg ctt ctt cag tca | 816 |
| 55 | Trp Thr Phe Met Leu Pro Phe Leu Arg Leu Ser Trp Leu Leu Gln Ser |     |



EP 1 576 166 B1

|    |   |     |     |      |
|----|---|-----|-----|------|
|    | 260   | 265 | 270 |      |
| 5  | atc att ttt gtt agt cag atg cca act cat tat tat gac tat tac aga |     |     | 864  |
|    | Ile Ile Phe Val Ser Gln Met Pro Thr His Tyr Tyr Asp Tyr Tyr Arg |     |     |      |
|    | 275   | 280 | 285 |      |
| 10 | aat act gcg att tat gaa cag gtt ggt ctc tct ttg cac tgg gct tgg |     |     | 912  |
|    | Asn Thr Ala Ile Tyr Glu Gln Val Gly Leu Ser Leu His Trp Ala Trp |     |     |      |
|    | 290   | 295 | 300 |      |
| 15 | tca ttg ggt caa ttg tat ttc cta ccc gat tgg tca act aga ata atg |     |     | 960  |
|    | Ser Leu Gly Gln Leu Tyr Phe Leu Pro Asp Trp Ser Thr Arg Ile Met |     |     |      |
| 20 | 305   | 310 | 315 | 320  |
| 25 | ttc ttc ctt gtt tct cat ctt gtt gga ggt ttc ctg ctc tct cat gta |     |     | 1008 |
|    | Phe Phe Leu Val Ser His Leu Val Gly Gly Phe Leu Leu Ser His Val |     |     |      |
|    | 325   | 330 | 335 |      |
| 30 | gtt act ttc aat cat tat tca gtg gag aag ttt gca ttg agc tcg aac |     |     | 1056 |
|    | Val Thr Phe Asn His Tyr Ser Val Glu Lys Phe Ala Leu Ser Ser Asn |     |     |      |
|    | 340   | 345 | 350 |      |
| 35 | atc atg tca aat tac gct tgt ctt caa atc atg acc aca aga aat atg |     |     | 1104 |
|    | Ile Met Ser Asn Tyr Ala Cys Leu Gln Ile Met Thr Thr Arg Asn Met |     |     |      |
| 40 | 355   | 360 | 365 |      |
| 45 | aga cct gga aga ttc att gac tgg ctt tgg gga ggt ctt aac tat cag |     |     | 1152 |
|    | Arg Pro Gly Arg Phe Ile Asp Trp Leu Trp Gly Gly Leu Asn Tyr Gln |     |     |      |
|    | 370   | 375 | 380 |      |
| 50 | att gag cac cat ctt ttc cca acg atg cca cga cac aac ttg aac act |     |     | 1200 |
|    | Ile Glu His His Leu Phe Pro Thr Met Pro Arg His Asn Leu Asn Thr |     |     |      |
|    | 385   | 390 | 395 | 400  |
| 55 | gtt atg cca ctt gtt aag gag ttt gca gca gca aat ggt tta cca tac |     |     | 1248 |

EP 1 576 166 B1

Val Met Pro Leu Val Lys Glu Phe Ala Ala Ala Asn Gly Leu Pro Tyr  
 405 410 415

5 atg gtc gac gat tat ttc aca gga ttc tgg ctt gaa att gag caa ttc 1296

10 Met Val Asp Asp Tyr Phe Thr Gly Phe Trp Leu Glu Ile Glu Gln Phe  
 420 425 430

15 cga aat att gca aat gtt gct gct aaa ttg act aaa aag att gcc tag 1344

Arg Asn Ile Ala Asn Val Ala Ala Lys Leu Thr Lys Lys Ile Ala  
 435 440 445

<210> 8

<211> 447

20 <212> PRT

<213> Ceratodon purpureus

<400> 8

25 Met Val Leu Arg Glu Gln Glu His Glu Pro Phe Phe Ile Lys Ile Asp  
 1 5 10 15

30 Gly Lys Trp Cys Gln Ile Asp Asp Ala Val Leu Arg Ser His Pro Gly  
 20 25 30

35 Gly Ser Ala Ile Thr Thr Tyr Lys Asn Met Asp Ala Thr Thr Val Phe  
 35 40 45

40 His Thr Phe His Thr Gly Ser Lys Glu Ala Tyr Gln Trp Leu Thr Glu  
 50 55 60

45 Leu Lys Lys Glu Cys Pro Thr Gln Glu Pro Glu Ile Pro Asp Ile Lys  
 65 70 75 80

50 Asp Asp Pro Ile Lys Gly Ile Asp Asp Val Asn Met Gly Thr Phe Asn  
 85 90 95

55

EP 1 576 166 B1

Ile Ser Glu Lys Arg Ser Ala Gln Ile Asn Lys Ser Phe Thr Asp Leu  
 100 105 110  
 5  
 Arg Met Arg Val Arg Ala Glu Gly Leu Met Asp Gly Ser Pro Leu Phe  
 115 120 125  
 10  
 Tyr Ile Arg Lys Ile Leu Glu Thr Ile Phe Thr Ile Leu Phe Ala Phe  
 130 135 140  
 15  
 Tyr Leu Gln Tyr His Thr Tyr Tyr Leu Pro Ser Ala Ile Leu Met Gly  
 145 150 155 160  
 20  
 Val Ala Trp Gln Gln Leu Gly Trp Leu Ile His Glu Phe Ala His His  
 165 170 175  
 25  
 Gln Leu Phe Lys Asn Arg Tyr Tyr Asn Asp Leu Ala Ser Tyr Phe Val  
 180 185 190  
 30  
 Gly Asn Phe Leu Gln Gly Phe Ser Ser Gly Gly Trp Lys Glu Gln His  
 195 200 205  
 35  
 Asn Val His His Ala Ala Thr Asn Val Val Gly Arg Asp Gly Asp Leu  
 210 215 220  
 40  
 Asp Leu Val Pro Phe Tyr Ala Thr Val Ala Glu His Leu Asn Asn Tyr  
 225 230 235 240  
 45  
 Ser Gln Asp Ser Trp Val Met Thr Leu Phe Arg Trp Gln His Val His  
 245 250 255  
 50  
 Trp Thr Phe Met Leu Pro Phe Leu Arg Leu Ser Trp Leu Leu Gln Ser  
 260 265 270  
 55  
 Ile Ile Phe Val Ser Gln Met Pro Thr His Tyr Tyr Asp Tyr Tyr Arg

EP 1 576 166 B1

|    |   |  |     |  |     |
|----|---|--|-----|--|-----|
|    | 275   |  | 280 |  | 285 |
| 5  | Asn Thr Ala Ile Tyr Glu Gln Val Gly Leu Ser Leu His Trp Ala Trp |  |     |  |     |
|    | 290   |  | 295 |  | 300 |
| 10 | Ser Leu Gly Gln Leu Tyr Phe Leu Pro Asp Trp Ser Thr Arg Ile Met |  |     |  |     |
|    | 305   |  | 310 |  | 320 |
| 15 | Phe Phe Leu Val Ser His Leu Val Gly Gly Phe Leu Leu Ser His Val |  |     |  |     |
|    |   |  | 325 |  | 330 |
|    |   |  |     |  | 335 |
| 20 | Val Thr Phe Asn His Tyr Ser Val Glu Lys Phe Ala Leu Ser Ser Asn |  |     |  |     |
|    |   |  | 340 |  | 345 |
|    |   |  |     |  | 350 |
| 25 | Ile Met Ser Asn Tyr Ala Cys Leu Gln Ile Met Thr Thr Arg Asn Met |  |     |  |     |
|    | 355   |  | 360 |  | 365 |
| 30 | Arg Pro Gly Arg Phe Ile Asp Trp Leu Trp Gly Gly Leu Asn Tyr Gln |  |     |  |     |
|    | 370   |  | 375 |  | 380 |
| 35 | Ile Glu His His Leu Phe Pro Thr Met Pro Arg His Asn Leu Asn Thr |  |     |  |     |
|    | 385   |  | 390 |  | 395 |
|    |   |  |     |  | 400 |
| 40 | Val Met Pro Leu Val Lys Glu Phe Ala Ala Ala Asn Gly Leu Pro Tyr |  |     |  |     |
|    |   |  | 405 |  | 410 |
|    |   |  |     |  | 415 |
| 45 | Met Val Asp Asp Tyr Phe Thr Gly Phe Trp Leu Glu Ile Glu Gln Phe |  |     |  |     |
|    |   |  | 420 |  | 425 |
|    |   |  |     |  | 430 |
| 50 | Arg Asn Ile Ala Asn Val Ala Ala Lys Leu Thr Lys Lys Ile Ala     |  |     |  |     |
|    | 435   |  | 440 |  | 445 |

<210> 9

<211> 1443

<212> DNA

55 <213> Physcomitrella patens

<220>

<221> CDS

EP 1 576 166 B1

<222> (1)..(1443)

<223> delta-5-desaturase

<400> 9

5  
atg gcg ccc cac tct gcg gat act gct ggg ctc gtg cct tct gac gaa 48  
Met Ala Pro His Ser Ala Asp Thr Ala Gly Leu Val Pro Ser Asp Glu  
10 1 5 10 15  
ttg agg cta cga acg tcg aat tca aag ggt ccc gaa caa gag caa act 96  
Leu Arg Leu Arg Thr Ser Asn Ser Lys Gly Pro Glu Gln Glu Gln Thr  
15 20 25 30  
ttg aag aag tac acc ctt gaa gat gtc agc cgc cac aac acc cca gca 144  
Leu Lys Lys Tyr Thr Leu Glu Asp Val Ser Arg His Asn Thr Pro Ala  
20 35 40 45  
gat tgt tgg ttg gtg ata tgg ggc aaa gtc tac gat gtc aca agc tgg 192  
Asp Cys Trp Leu Val Ile Trp Gly Lys Val Tyr Asp Val Thr Ser Trp  
25 50 55 60  
att ccc aat cat ccg ggg ggc agt ctc atc cac gta aaa gca ggg cag 240  
Ile Pro Asn His Pro Gly Gly Ser Leu Ile His Val Lys Ala Gly Gln  
30 65 70 75 80  
gat tcc act cag ctt ttc gat tcc tat cac ccc ctt tat gtc agg aaa 288  
Asp Ser Thr Gln Leu Phe Asp Ser Tyr His Pro Leu Tyr Val Arg Lys  
35 85 90 95  
atg ctc gcg aag tac tgt att ggg gaa tka gta ccg tct gct ggt gat 336  
Met Leu Ala Lys Tyr Cys Ile Gly Glu Xaa Val Pro Ser Ala Gly Asp  
40  
50  
55

EP 1 576 166 B1

|    |   |     |     |     |     |     |
|----|---|-----|-----|-----|-----|-----|
|    | 100   |     | 105 |     | 110 |     |
| 5  | gac aag ttt aag aaa gca act ctg rag tat gca gat gcc gaa aat gaa 384 |     |     |     |     |     |
|    | Asp Lys Phe Lys Lys Ala Thr Leu Xaa Tyr Ala Asp Ala Glu Asn Glu     |     |     |     |     |     |
|    | 115   |     | 120 |     | 125 |     |
| 10 | gat ttc tat ttg gtt gtg aag caa cga gtt gaa tct tat ttc aag agt 432 |     |     |     |     |     |
|    | Asp Phe Tyr Leu Val Val Lys Gln Arg Val Glu Ser Tyr Phe Lys Ser     |     |     |     |     |     |
|    | 130   |     | 135 |     | 140 |     |
| 15 | aac aag ata aac ccc caa att cat cca cat atg atc ctg aag tca ttg 480 |     |     |     |     |     |
|    | Asn Lys Ile Asn Pro Gln Ile His Pro His Met Ile Leu Lys Ser Leu     |     |     |     |     |     |
| 20 | 145   |     | 150 |     | 155 | 160 |
| 25 | ttc att ctt ggg gga tat ttc gcc agt tac tat tta gcg ttc ttc tgg 528 |     |     |     |     |     |
|    | Phe Ile Leu Gly Gly Tyr Phe Ala Ser Tyr Tyr Leu Ala Phe Phe Trp     |     |     |     |     |     |
|    |   | 165 |     | 170 |     | 175 |
| 30 | tct tca agt gtc ctt gtt tct ttg ttt ttc gca ttg tgg atg ggg ttc 576 |     |     |     |     |     |
|    | Ser Ser Ser Val Leu Val Ser Leu Phe Phe Ala Leu Trp Met Gly Phe     |     |     |     |     |     |
|    |   | 180 |     | 185 |     | 190 |
| 35 | ttc gca gcg gaa gtc ggc gtg tcg att caa cat gat gga aat cat ggt 624 |     |     |     |     |     |
|    | Phe Ala Ala Glu Val Gly Val Ser Ile Gln His Asp Gly Asn His Gly     |     |     |     |     |     |
| 40 | 195   |     | 200 |     | 205 |     |
| 45 | tca tac act aaa tgg cgt ggc ttt gga tat atc atg gga gcc tcc cta 672 |     |     |     |     |     |
|    | Ser Tyr Thr Lys Trp Arg Gly Phe Gly Tyr Ile Met Gly Ala Ser Leu     |     |     |     |     |     |
|    | 210   |     | 215 |     | 220 |     |
| 50 | gat cta gtc gga gcc agt agc ttc atg tgg aga cag caa cac gtt gtg 720 |     |     |     |     |     |
|    | Asp Leu Val Gly Ala Ser Ser Phe Met Trp Arg Gln Gln His Val Val     |     |     |     |     |     |
|    | 225   |     | 230 |     | 235 | 240 |
| 55 | gga cat cac tcg ttt aca aat gtg gac aac tac gat cct gat att cgt 768 |     |     |     |     |     |

EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
|    | Gly | His | His | Ser | Phe | Thr | Asn | Val | Asp | Asn | Tyr | Asp | Pro | Asp | Ile | Arg |      |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |      |
| 5  | gtg | aaa | gat | cca | gat | gtc | agg | agg | gtt | gcg | acc | aca | caa | cca | aga | caa | 816  |
|    | Val | Lys | Asp | Pro | Asp | Val | Arg | Arg | Val | Ala | Thr | Thr | Gln | Pro | Arg | Gln |      |
| 10 |     |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |      |
|    | tgg | tat | cat | gcg | tat | cag | cat | atc | tac | ctg | gca | gta | tta | tat | gga | act | 864  |
| 15 | Trp | Tyr | His | Ala | Tyr | Gln | His | Ile | Tyr | Leu | Ala | Val | Leu | Tyr | Gly | Thr |      |
|    |     |     |     | 275 |     |     |     | 280 |     |     |     |     |     |     | 285 |     |      |
|    | cta | gct | ctt | aag | agt | att | ttt | cta | gat | gat | ttc | ctt | gcg | tac | ttc | aca | 912  |
| 20 | Leu | Ala | Leu | Lys | Ser | Ile | Phe | Leu | Asp | Asp | Phe | Leu | Ala | Tyr | Phe | Thr |      |
|    |     |     |     | 290 |     |     |     | 295 |     |     |     |     |     | 300 |     |     |      |
|    | gga | tca | att | ggc | cct | gtc | aag | gtg | gcg | aaa | atg | acc | ccc | ctg | gag | ttc | 960  |
| 25 | Gly | Ser | Ile | Gly | Pro | Val | Lys | Val | Ala | Lys | Met | Thr | Pro | Leu | Glu | Phe |      |
|    |     |     |     | 305 |     |     | 310 |     |     |     | 315 |     |     |     | 320 |     |      |
| 30 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|    | aac | atc | ttc | ttt | cag | gga | aag | ctg | cta | tat | gcg | ttc | tac | atg | ttc | gtg | 1008 |
| 35 | Asn | Ile | Phe | Phe | Gln | Gly | Lys | Leu | Leu | Tyr | Ala | Phe | Tyr | Met | Phe | Val |      |
|    |     |     |     |     | 325 |     |     |     |     |     | 330 |     |     |     | 335 |     |      |
|    | ttg | cca | tct | gtg | tac | ggg | ggt | cac | tcc | gga | gga | act | ttc | ttg | gca | cta | 1056 |
| 40 | Leu | Pro | Ser | Val | Tyr | Gly | Val | His | Ser | Gly | Gly | Thr | Phe | Leu | Ala | Leu |      |
|    |     |     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |      |
|    | tat | gtg | gct | tct | cag | ctc | att | aca | ggg | tgg | atg | tta | gct | ttt | ctt | ttt | 1104 |
| 45 | Tyr | Val | Ala | Ser | Gln | Leu | Ile | Thr | Gly | Trp | Met | Leu | Ala | Phe | Leu | Phe |      |
|    |     |     |     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |      |
| 50 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|    | caa | gta | gca | cat | gtc | gtg | gat | gat | ggt | gca | ttt | cct | aca | cca | gaa | ggt | 1152 |
| 55 | Gln | Val | Ala | His | Val | Val | Asp | Asp | Val | Ala | Phe | Pro | Thr | Pro | Glu | Gly |      |
|    |     |     |     |     | 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |      |

EP 1 576 166 B1

5 ggg aag gtg aag gga gga tgg gct gca atg cag gtt gca aca act acg 1200  
 Gly Lys Val Lys Gly Gly Trp Ala Ala Met Gln Val Ala Thr Thr Thr  
 385 390 395 400

10 gat ttc agt cca cgc tca tgg ttc tgg ggt cat gtc tct gga gga tta 1248  
 Asp Phe Ser Pro Arg Ser Trp Phe Trp Gly His Val Ser Gly Gly Leu  
 405 410 415

15 aac aac caa att gag cat cat ctg ttt cca gga gtg tgc cat gtt cat 1296  
 Asn Asn Gln Ile Glu His His Leu Phe Pro Gly Val Cys His Val His  
 420 425 430

20 tat cca gcc att cag cct att gtc gag aag acg tgc aag gaa ttc gat 1344  
 Tyr Pro Ala Ile Gln Pro Ile Val Glu Lys Thr Cys Lys Glu Phe Asp  
 435 440 445

30 gtg cct tat gta gcc tac cca act ttt tgg act gcg ttg aga gcc cac 1392  
 Val Pro Tyr Val Ala Tyr Pro Thr Phe Trp Thr Ala Leu Arg Ala His  
 450 455 460

35 ttt gcg cat ttg aaa aag gtt gga ttg aca gag ttt cgg ctc gat ggc 1440  
 Phe Ala His Leu Lys Lys Val Gly Leu Thr Glu Phe Arg Leu Asp Gly  
 465 470 475 480

40 tga 1443

45 <210> 10  
 <211> 480  
 <212> PRT  
 <213> Physcomitrella patens

50 <400> 10

Met Ala Pro His Ser Ala Asp Thr Ala Gly Leu Val Pro Ser Asp Glu

55



EP 1 576 166 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |     |     | 15  |     |
| 5  | Leu | Arg | Leu | Arg | Thr | Ser | Asn | Ser | Lys | Gly | Pro | Glu | Gln | Glu | Gln | Thr |
|    |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| 10 | Leu | Lys | Lys | Tyr | Thr | Leu | Glu | Asp | Val | Ser | Arg | His | Asn | Thr | Pro | Ala |
|    |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |
| 15 | Asp | Cys | Trp | Leu | Val | Ile | Trp | Gly | Lys | Val | Tyr | Asp | Val | Thr | Ser | Trp |
|    |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |
| 20 | Ile | Pro | Asn | His | Pro | Gly | Gly | Ser | Leu | Ile | His | Val | Lys | Ala | Gly | Gln |
|    |     |     |     | 65  |     |     |     |     | 70  |     |     |     | 75  |     |     | 80  |
| 25 | Asp | Ser | Thr | Gln | Leu | Phe | Asp | Ser | Tyr | His | Pro | Leu | Tyr | Val | Arg | Lys |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 85  |     | 90  |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 95  |
| 30 | Met | Leu | Ala | Lys | Tyr | Cys | Ile | Gly | Glu | Xaa | Val | Pro | Ser | Ala | Gly | Asp |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 100 |     | 105 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 110 |
| 35 | Asp | Lys | Phe | Lys | Lys | Ala | Thr | Leu | Xaa | Tyr | Ala | Asp | Ala | Glu | Asn | Glu |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 115 |     | 120 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 125 |
| 40 | Asp | Phe | Tyr | Leu | Val | Val | Lys | Gln | Arg | Val | Glu | Ser | Tyr | Phe | Lys | Ser |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 130 |     | 135 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 140 |
| 45 | Asn | Lys | Ile | Asn | Pro | Gln | Ile | His | Pro | His | Met | Ile | Leu | Lys | Ser | Leu |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 145 |     | 150 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 155 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 160 |
| 50 | Phe | Ile | Leu | Gly | Gly | Tyr | Phe | Ala | Ser | Tyr | Tyr | Leu | Ala | Phe | Phe | Trp |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 165 |     | 170 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 175 |
| 55 | Ser | Ser | Ser | Val | Leu | Val | Ser | Leu | Phe | Phe | Ala | Leu | Trp | Met | Gly | Phe |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     | 180 |     | 185 |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 190 |

EP 1 576 166 B1

Phe Ala Ala Glu Val Gly Val Ser Ile Gln His Asp Gly Asn His Gly  
 195 200 205

5

Ser Tyr Thr Lys Trp Arg Gly Phe Gly Tyr Ile Met Gly Ala Ser Leu  
 210 215 220

10

Asp Leu Val Gly Ala Ser Ser Phe Met Trp Arg Gln Gln His Val Val  
 225 230 235 240

15

Gly His His Ser Phe Thr Asn Val Asp Asn Tyr Asp Pro Asp Ile Arg  
 245 250 255

20

Val Lys Asp Pro Asp Val Arg Arg Val Ala Thr Thr Gln Pro Arg Gln  
 260 265 270

25

Trp Tyr His Ala Tyr Gln His Ile Tyr Leu Ala Val Leu Tyr Gly Thr  
 275 280 285

30

Leu Ala Leu Lys Ser Ile Phe Leu Asp Asp Phe Leu Ala Tyr Phe Thr  
 290 295 300

35

Gly Ser Ile Gly Pro Val Lys Val Ala Lys Met Thr Pro Leu Glu Phe  
 305 310 315 320

40

Asn Ile Phe Phe Gln Gly Lys Leu Leu Tyr Ala Phe Tyr Met Phe Val  
 325 330 335

45

Leu Pro Ser Val Tyr Gly Val His Ser Gly Gly Thr Phe Leu Ala Leu  
 340 345 350

50

Tyr Val Ala Ser Gln Leu Ile Thr Gly Trp Met Leu Ala Phe Leu Phe  
 355 360 365

55

Gln Val Ala His Val Val Asp Asp Val Ala Phe Pro Thr Pro Glu Gly  
 370 375 380

Gly Lys Val Lys Gly Gly Trp Ala Ala Met Gln Val Ala Thr Thr Thr  
 385 390 395 400

Asp Phe Ser Pro Arg Ser Trp Phe Trp Gly His Val Ser Gly Gly Leu  
 405 410 415

Asn Asn Gln Ile Glu His His Leu Phe Pro Gly Val Cys His Val His  
 420 425 430


Tyr Pro Ala Ile Gln Pro Ile Val Glu Lys Thr Cys Lys Glu Phe Asp  
 435 440 445

Val Pro Tyr Val Ala Tyr Pro Thr Phe Trp Thr Ala Leu Arg Ala His  
 450 455 460

Phe Ala His Leu Lys Lys Val Gly Leu Thr Glu Phe Arg Leu Asp Gly  
 465 470 475 480

Claims

1. A process for the production of compounds of the following general formula I




in transgenic oil producing plant with a content of at least 1 % by weight of said compounds referred to the total lipid content of said oil producing plant which comprises the following steps:

- a) introduction of at least one nucleic acid in a transgenic oil producing plant, which encodes a  $\Delta$ -9-elongase having the sequence SEQ ID NO:3, and
- b) introduction of at least one second nucleic acid which encodes a  $\Delta$ -8-desaturase having the sequence SEQ ID NO:1, and
- c) if necessary introduction of at least a third nucleic acid, which encodes a  $\Delta$ -5-desaturase having the sequence SEQ ID NO:5, 7 or 9, and
- d) cultivating and harvesting of said oil producing plant; and


where the variables and substituents in formula I have the following meanings:

R<sup>1</sup> = hydroxyl-, Coenzyme A-(Thioester), phosphatidylcholine-, phosphatidyl-ethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, sphingolipid-, glycosphingolipid- or a

residue of the general formula II:



R<sup>2</sup> = hydrogen-, phosphatidylcholine-, phosphatidylethanolamine-, phosphatidylglycerol-, diphosphatidylglycerol-, phosphatidylserine-, phosphatidylinositol-, shingolipid-, glycoshingolipid-, glycoshingolipid- or saturated or unsaturated C<sub>2</sub>-C<sub>24</sub>-alkylcarbonyl-,  
 R<sup>3</sup> = hydrogen-, saturated or unsaturated C<sub>2</sub>-C<sub>24</sub>-alkylcarbonyl-, or R<sup>2</sup> and R<sup>3</sup> independent of each other a residue of the formula Ia:




n = 3, 4 or 6, m = 3, 4 or 5 and p = 0 or 3.

2. The process as claimed in claim 1, wherein the substituents R<sup>2</sup> and R<sup>3</sup> are independent of each other saturated or unsaturated C<sub>10</sub>-C<sub>22</sub>-alkylcarbonyl-.
3. The process as claimed in any of the claims 1 to 2, wherein the substituents R<sup>2</sup> and R<sup>3</sup> are independent of each other saturated or unsaturated C<sub>16</sub>-, C<sub>18</sub>-, C<sub>20</sub>- or C<sub>22</sub>-alkyl-carbonyl-.
4. The process as claimed in any of the claims 1 to 3, wherein the substituents R<sup>2</sup> and R<sup>3</sup> are independent of each other unsaturated C<sub>16</sub>-, C<sub>18</sub>-, C<sub>20</sub>- or C<sub>22</sub>-alkylcarbonyl- with at least three double bonds.
5. The process as claimed in any of the claims 1 to 4, wherein the transgenic plant is selected from the group consisting of rapeseed, poppy, mustard, hemp, castor bean, sesame, olive, calendula, punica, hazel nut, almond, macadamia, avocado, pumpkin, walnut, laurel, pistachio, primrose, canola, peanut, linseed, soybean, safflower, sunflower and borage.
6. The process as claimed in any of the claims 1 to 5, wherein the compounds of the general formula I are isolated in the form of their oils, lipids or free fatty acids.
7. The process as claimed in any of the claims 1 to 6, wherein the compounds of the general formula I are isolated in a concentration of at least 5 % by weight referred to the total lipid content.
8. An isolated nucleic acid comprising a nucleotide sequence which encodes a Δ-8-desaturase having a nucleic acid sequence depicted in SEQ ID NO: 1.
9. polypeptide encoded by an isolated nucleic acid sequence as claimed in claims 8.
10. A gene construct comprising an isolated nucleic acid having the sequence SEQ ID NO: 1, where the nucleic acid is functionally linked to one or more regulatory signals.
11. An oil producing plant comprising at least one nucleic acid as claimed in claim 8 or a gene construct as claimed in claim 10.

## Patentansprüche

1. Verfahren zum Herstellen von Verbindungen der folgenden allgemeinen Formel I




in einer transgenen ölproduzierenden Pflanze mit einem Gehalt von wenigstens 1 Gew.-% an den Verbindungen bezogen auf den Gesamtlipidgehalt der ölproduzierenden Pflanze, umfassend folgende Schritte:

- Einführen wenigstens einer Nukleinsäure, die eine  $\Delta$ -9-Elongase kodiert, mit der Sequenz SEQ ID NO:3 in eine transgene ölproduzierende Pflanze und
- Einführen wenigstens einer zweiten Nukleinsäure, die eine  $\Delta$ -8-Desaturase kodiert, mit der Sequenz SEQ ID NO:1 und
- nötigenfalls Einführen wenigstens einer dritten Nukleinsäure, die eine  $\Delta$ -5-Desaturase kodiert, mit der Sequenz SEQ ID NO:5, 7 oder 9 und
- Kultivieren und Ernten der ölproduzierenden Pflanze; und


wobei die Variablen und Substituenten in Formel I folgende Bedeutungen haben:

$R^1$  = Hydroxy-, Coenzym A- (Thioester), Phosphatidylcholin-, Phosphatidyl-, Ethanolamin-, Phosphatidylglycerol-, Diphosphatidylglycerol-, Phosphatidylserin-, Phosphatidylinositol-, Sphingolipid-, Glycosphingolipid- oder ein Rest der allgemeinen Formel II:



$R^2$  = Wasserstoff-, Phosphatidylcholin-, Phosphatidylethanolamin-, Phosphatidylglycerol-, Diphosphatidylglycerol-, Phosphatidylserin-, Phosphatidylinositol-, Sphingolipid-, Glycosphingolipid-, Glycosphingolipid- oder gesättigtes oder nichtgesättigtes  $\text{C}_2$ - $\text{C}_{24}$ -Alkylcarbonyl,

$R^3$  = Wasserstoff-, gesättigtes oder nichtgesättigtes  $\text{C}_2$ - $\text{C}_{24}$ -Alkylcarbonyl-, oder  $R^2$  und  $R^3$  sind unabhängig voneinander ein Rest der Formel Ia:



$n = 3, 4$  oder  $6$ ,  $m = 3, 4$  oder  $5$  und  $p = 0$  oder  $3$ .


- Verfahren gemäß Anspruch 1, wobei die Substituenten  $R^2$  und  $R^3$  unabhängig voneinander gesättigtes oder nichtgesättigtes  $\text{C}_{10}$ - $\text{C}_{22}$ -Alkylcarbonyl- sind.
- Verfahren gemäß einem der Ansprüche 1 bis 2, wobei die Substituenten  $R^2$  und  $R^3$  unabhängig voneinander ge-

sättigtes oder nichtgesättigtes C<sub>16</sub>-, C<sub>18</sub>-, C<sub>20</sub>- oder C<sub>22</sub>-Alkylcarbonyl- sind.

4. Verfahren gemäß einem der Ansprüche 1 bis 3, wobei die Substituenten R<sup>2</sup> und R<sup>3</sup> unabhängig voneinander nicht-gesättigtes C<sub>16</sub>-, C<sub>18</sub>-, C<sub>20</sub>- oder C<sub>22</sub>-Alkylcarbonyl- mit wenigstens drei Doppelbindungen sind.
5. Verfahren gemäß einem der Ansprüche 1 bis 4, wobei die transgene Pflanze ausgewählt ist aus der Gruppe bestehend aus Raps, Mohn, Senf, Hanf, Castorbohne, Sesam, Olive, Calendula, Punica, Haselnuss, Mandel, Macadamia, Avocado, Kürbis, Walnuss, Lorbeer, Pistazie, Primel, Canola, Erdnuss, Leinsamen, Sojabohne, Distel, Sonnenblume und Borago.
6. Verfahren gemäß einem der Ansprüche 1 bis 5, wobei die Verbindungen der allgemeinen Formel I in der Form ihrer Öle, Lipide von freien Fettsäuren isoliert werden.
7. Verfahren gemäß einem der Ansprüche 1 bis 6, wobei die Verbindungen der allgemeinen Formel I in einer Konzentration von wenigstens 5 Gew.-% bezogen auf den Gesamtlipidgehalt isoliert werden.
8. Isolierte Nukleinsäure, umfassend eine Nukleotidsequenz, die eine Δ-8-Desaturase kodiert, mit der in SEQ ID NO:1 dargestellten Sequenz.
9. Polypeptid, kodiert von einer isolierten Nukleinsäuresequenz gemäß Anspruch 8.
10. Genkonstrukt, umfassend eine isolierte Nukleinsäure mit der Sequenz SEQ ID NO:1, wobei die Nukleinsäure mit einem oder mehreren regulatorischen Signalen funktionell verbunden ist.
11. Ölproduzierende Pflanze, umfassend wenigstens eine Nukleinsäure gemäß Anspruch 8 oder ein Genkonstrukt gemäß Anspruch 10.

### Revendications

1. Procédé pour la production de composés de la formule générale suivante I :




dans une plante oléagineuse transgénique ayant une teneur d'au moins 1 % en poids desdits composés par rapport à la teneur totale en lipides de ladite plante oléagineuse qui comprend les étapes suivantes :

- a) introduction d'au moins un acide nucléique dans une plante oléagineuse transgénique qui code pour une Δ9-élongase ayant la séquence SEQ ID NO: 3, et
- b) introduction d'au moins un deuxième activités qui code pour une Δ-8-désaturase ayant la séquence SEQ ID NO: 1, et
- c) si nécessaire, introduction d'au moins un troisième acide nucléique, qui code pour une Δ-5-désaturase ayant la séquence SEQ ID NO: 5, 7 ou 9, et
- d) culture et récolte de ladite plante oléagineuse ;

et


les variables et substituants dans la formule I ont les définitions suivantes :

R<sup>1</sup> = hydroxyl-, coenzyme A-(thioester), phosphatidylcholine-, phosphatidyléthanolamine-, phosphatidylglycérol-, diphosphatidylglycérol-, phosphatidylsérine-, phosphatidylinositol-, sphingolipide-, glycosphingolipide-, ou un résidu de formule générale II :



R<sup>2</sup> = hydrogène-, phosphatidylcholine-, phosphatidyléthanolamine-, phosphatidylglycérol-, diphosphatidylglycérol-, phosphatidylsérine-, phosphatidylinositol-, sphingolipide-, glycosphingolipide- ou (alkyle en C<sub>2</sub>-C<sub>24</sub>)-carbonyle saturé ou insaturé,

R<sup>3</sup> = hydrogène-, (alkyle en C<sub>2</sub>-C<sub>24</sub>)-carbonyle saturé ou insaturé, ou R<sup>2</sup> et R<sup>3</sup> indépendamment l'un de l'autre un résidu de formule Ia :



n = 3, 4 ou 6, m = 3, 4 ou 5 et p = 0 ou 3.

2. Procédé selon la revendication 1, dans lequel les substituants R<sup>2</sup> et R<sup>3</sup> sont indépendamment l'un de l'autre un (alkyle en C<sub>10</sub>-C<sub>22</sub>)-carbonyle saturé ou insaturé.
3. Procédé selon l'une quelconque des revendications 1 à 2, dans lequel les substituants R<sup>2</sup> et R<sup>3</sup> sont indépendamment l'un de l'autre un (alkyle en C<sub>16</sub>, C<sub>18</sub>, C<sub>20</sub> ou C<sub>22</sub>)-carbonyle saturé ou insaturé.
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel les substituants R<sup>2</sup> et R<sup>3</sup> sont indépendamment l'un de l'autre un (alkyle en C<sub>16</sub>, C<sub>18</sub>, C<sub>20</sub> ou C<sub>22</sub>)-carbonyle insaturé avec au moins trois doubles liaisons.
5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la plante transgénique est choisie dans le groupe constitué du colza, du pavot, de la moutarde, du chanvre, du ricin, du sésame, de l'olive, du Calendula, du Punica, de la noisette, de la noix de macadamia, de l'avocat, de la citrouille, de la noix, du laurier, de la pistache, de l'onagre, du canola, de l'arachide, du lin, du soja, du carthame, du tournesol et de la bourrache.
6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel les composés de la formule générale I sont isolés sous la forme de leurs huiles, lipides ou acides gras libres.
7. Procédé selon l'une quelconque des revendications 1 à 6, dans lequel les composés de la formule générale I sont isolés à une concentration d'au moins 5 % en poids par rapport à la teneur en lipide totale.
8. Acide nucléique isolé comprenant une séquence nucléotidique qui code pour une Δ-8-désaturase ayant une séquence d'acide nucléique décrite dans SEQ ID NO: 1.
9. Polypeptide codé par une séquence d'acide nucléique isolée selon la revendication 8.
10. Construction génique comprenant un acide nucléique isolé ayant la séquence SEQ ID NO: 1, l'acide nucléique étant fonctionnellement lié à un ou plusieurs signaux régulateurs.
11. Plante oléagineuse comprenant au moins un acide nucléique selon la revendication 8 ou une construction génique selon la revendication 10.

FIG.1






FIG.2




FIG.3







FIG.4D




# FIG.5A




# FIG.5B



# FIG.5C



# FIG.5D



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 9113972 A [0006]
- WO 9311245 A [0006]
- WO 9411516 A [0006]
- WO 0034439 A [0006]
- EP 0550162 A [0006]
- WO 9418337 A [0006]
- WO 9730582 A [0006]
- WO 9721340 A [0006]
- WO 9518222 A [0006]
- EP 0794250 A [0006]
- WO 9306712 A [0006]
- US 5614393 A [0006]
- WO 9621022 A [0006]
- WO 0021557 A [0006]
- WO 9927111 A [0006]
- WO 9846763 A [0006]
- WO 9846764 A [0006]
- WO 9846765 A [0006]
- WO 9964616 A [0006]
- WO 9846776 A [0006]
- US 20020138874 A1 [0007]
- WO 02077213 A3 [0007]
- EP 388186 A [0052]
- WO 9519443 A [0052]
- EP 335528 A [0052]
- WO 9321334 A [0052]
- EP 249676 A [0052]
- US 5608152 A [0052] [0053]
- WO 9845461 A [0052] [0053]
- US 5504200 A [0052] [0053]
- WO 9113980 A [0052]
- WO 9515389 A [0052] [0053]
- WO 9523230 A [0052] [0053]
- WO 9916890 A [0052] [0053]
- US 5677474 A [0053]
- US 5530149 A [0053]
- EP 571741 A [0053]
- JP 6062870 A [0053]
- WO 9808962 A [0053]
- US 5689040 A [0053]
- EP 781849 A [0053]
- US 5565350 A [0092]
- WO 0015815 A [0092]

## Non-patent literature cited in the description

- **STUKEY et al.** *J. Biol. Chem.*, 1990, vol. 265, 20144-20149 [0006]
- **WADA et al.** *Nature*, 1990, vol. 347, 200-203 [0006]
- **HUANG et al.** *Lipids*, 1999, vol. 34, 649-659 [0006]
- **MCKEON et al.** *Methods in Enzymol.*, 1981, vol. 71, 12141-12147 [0006]
- **WANG et al.** *Plant Physiol. Biochem.*, 1988, vol. 26, 777-792 [0006]
- **BLIGH et al.** *Can. J. Biochem. Physiol.*, 1959, vol. 37, 911-917 [0030]
- **VICK et al.** *Plant Physiol.*, 1982, vol. 69, 1103-1108 [0030]
- **SAMBROOK et al.** *Molecular Cloning*. Cold Spring Harbor Laboratory, 1989 [0040]
- *Current Protocols in Molecular Biology*. John Wiley & Sons, 1985 [0040]
- *Nucleic Acids Hybridization: A Practical Approach*. IRL Press at Oxford University Press, 1985 [0040]
- *Essential Molecular Biology: A Practical Approach*. IRL Press at Oxford University Press, 1991 [0040]
- **WADA et al.** *Nucleic Acids Res.*, 1992, vol. 20, 2111-2118 [0043]
- **PATTEN, P.A. et al.** *Current Opinion in Biotechnology*, 1997, vol. 8, 724-733 [0044]
- **MOORE, J.C. et al.** *Journal of Molecular Biology*, 1997, vol. 272, 336-347 [0044]
- **NAPIER J.A.** Targeting of foreign proteins to the chloroplast. *Methods Mol. Biol.*, 1995, vol. 49, 369-376 [0045]
- **GUERINEAU F. ; WOOLSTON S. ; BROOKS L. ; MULLINEAUX P.** An expression cassette for targeting foreign proteins into chloroplast. *Nucleic Acids Res.*, 09 December 1988, vol. 16 (23), 11380 [0045] [0059]
- **FRANCK et al.** *Cell*, 1980, vol. 21, 285-294 [0052]
- **WARD et al.** *Plant. Mol. Biol.*, 1993, vol. 22, 361-366 [0052]
- **GATZ et al.** *Plant J.*, 1992, vol. 2, 397-404 [0052]
- **STOCKHAUS et al.** *EMBO J.*, 1989, vol. 8, 2445-245 [0052]
- **BAEUMLEIN et al.** *Mol Gen Genet*, 1991, vol. 225 (3), 459-67 [0052] [0053]
- **BAEUMLEIN et al.** *Plant J.*, 1992, vol. 2 (2), 233-239 [0052]

- **BAEUMLEIN et al.** *Plant Journal*, 1992, vol. 2 (2), 233-9 [0053]
- **SCHOUTEN, A. et al.** *Plant Mol. Biol.*, 1996, vol. 30, 781-792 [0059]
- **NAPIER J.A.** Targeting of foreign proteins to the chloroplast. *Methods Mol. Biol.*, 1995, vol. 49, 369-376 [0059]
- **GIELEN et al.** *EMBO J.*, 1984, vol. 3, 835 [0060] [0140]
- **T. MANIATIS ; E.F. FRITSCH ; J. SAMBROOK.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, 1989 [0061]
- **T.J. SILHAVY ; M.L. BERMAN ; L.W. ENQUIST.** Experiments with Gene Fusions. Cold Spring Harbor Laboratory, 1984 [0061]
- **AUSUBEL, F.M. et al.** Current Protocols in Molecular Biology. Greene Publishing Assoc. and Wiley-Interscience, 1987 [0061]
- **KERMODE.** *Crit. Rev. Plant Sci.*, 1996, vol. 15 (4), 285-423 [0066]
- **GALLIE et al.** *Nucl. Acids Res.*, 1987, vol. 15, 8693-8711 [0068]
- **ROMANOS, M.A. et al.** Foreign gene expression in yeast: a review. *Yeast*, 1992, vol. 8, 423-488 [0070]
- Hetero-logous gene expression in filamentous fungi. **VAN DEN HONDEL, C.A.M.J.J. et al.** More Gene Manipulations in Fungi. Academic Press, 1991, 396-428 [0070]
- Gene transfer systems and vector development for filamentous fungi. **VAN DEN HONDEL, C.A.M.J.J. ; PUNT, P.J. et al.** Applied Molecular Genetics of Fungi. Cambridge University Press, 1991, 1-28 [0070] [0081]
- Cloning Vectors. Elsevier, 1985 [0070]
- Methods in Plant Molecular Biology and Biotechnology. CRC Press, 71-119 [0070]
- **TOEPFER et al.** *Methods Enzymol.*, 1993, vol. 217, 66-78 [0076]
- **TOEPFER et al.** *Nucl. Acids Res.*, 1987, vol. 15, 5890 ff [0076]
- **SMITH, D.B. ; JOHNSON, K.S.** Gene. Pharmacia Biotech Inc, 1988, vol. 67, 31-40 [0079]
- **AMANN et al.** *Gene*, 1988, vol. 69, 301-315 [0080]
- **STUDIER et al.** Gene Expression Technology: Methods in Enzymology. Academic Press, 1990, vol. 185, 60-89 [0080]
- **BALDARI et al.** *Embo J.*, 1987, vol. 6, 229-234 [0081]
- **KURJAN.** *Cell*, 1982, vol. 30, 933-943 [0081]
- **SCHULTZ et al.** *Gene*, 1987, vol. 54, 113-123 [0081]
- **SMITH et al.** *Mol. Cell Biol.*, 1983, vol. 3, 2156-2165 [0082]
- **LUCKLOW ; SUMMERS.** *Virology*, 1989, vol. 170, 31-39 [0082]
- **BECKER, D. et al.** New plant binary vectors with selectable markers located proximal to the left border. *Plant Mol. Biol.*, 1992, vol. 20, 1195-1197 [0083]
- **BEVAN, M.W.** Binary Agrobacterium vectors for plant transformation. *Nucl. Acid. Res.*, 1984, vol. 12, 8711-8721 [0083]
- **SEED, B.** *Nature*, 1987, vol. 329, 840 [0084]
- **KAUFMAN et al.** *EMBO J.*, 1987, vol. 6, 187-195 [0084]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0084]
- **SAMBROOK, J. et al.** Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, 1989 [0087]
- **F.M. AUSUBEL et al.** Current protocols in molecular biology. John Wiley and Sons, 1994 [0087]
- **D.M. GLOVER et al.** DNA Cloning. IRL Press, 1995, vol. 1 [0087]
- **KAISER et al.** Methods in Yeast Genetics. Cold Spring Harbor Laboratory Press, 1994 [0087]
- Guide to Yeast Genetics and Molecular Biology. **GUTHRIE et al.** Methods in Enzymology. Academic Press, 1994 [0087]
- Techniques for Gene Transfer, in: Transgenic Plants. **B. JENES et al.** Engineering and Utilization. Academic Press, 1993, vol. 1, 128-143 [0088]
- Potrykus *Annu. Rev. Plant Physiol. Plant Molec. Biol.* *Potrykus Annu. Rev. Plant Physiol. Plant Molec. Biol.*, 1991, vol. 42, 205-225 [0088]
- **BEVAN et al.** *Nucl. Acids Res.*, 1984, vol. 12, 8711 [0088]
- **HÖFGEN ; WILLMITZER.** *Nucl. Acid Res.*, 1988, vol. 16, 9877 [0088]
- Vectors for Gene Transfer in Higher Plants. **F.F. WHITE.** Transgenic Plants, Vol. 1, Engineering and Utilization. Academic Press, 1993, vol. 1, 15-38 [0088]
- **GOEDDEL.** Gene Expression Technology: Methods in Enzymology. Academic Press, 1990, vol. 185 [0094]
- **GOTTESMAN, S.** Gene Expression Technology: Methods in Enzymology. Academic Press, 1990, vol. 185, 119-128 [0095]
- **SANGER et al.** *Proc. Natl. Acad. Sci. USA*, 1977, vol. 74, 5463-5467 [0122]
- **WALLIS ; BROWSE.** *Archives of Biochem. and Biophysics*, 1999, vol. 365 (2) [0125]
- **QI, B. ; BEAUDOIN, F. ; FRASER, T. ; STOBART, A. K. ; NAPIER, J.A. ; LAZARUS, C.M.** Identification of a cDNA encoding a novel C18- $\Delta$ -9-polyunsaturated fatty acid-specific elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana*. *FEBS Letters*, 2002, vol. 510, 159-165 [0129]
- **CLOUGH ; BENT.** Floral dip: a simplified method for Agrobacterium-mediated transformation of *Arabidopsis thaliana*. *Plant Journal*, 1998, vol. 16, 735-743 [0131]

## EP 1 576 166 B1

- **MCCORMAC, A.C. ; ELIOTT, M.C. ; CHEN, D-F.** pBECKS. A flexible series of binary vectors for Agrobacterium-mediated plant transformation. *Molecular Biotechnology*, 1997, vol. 8, 199-213 [0135]
- **XIANG, C. ; HAN, P. ; LUTZIGER, I. ; WANG, K. ; OLIVER, D.J.** A mini binary vector series for plant transformation. *Plant Molecular Biology*, 1999, vol. 40, 711-717 [0135]
- **BECKER, D. et al.** *Plant Mol. Biol.*, 1992, vol. 20, 1195-1197 [0136]
- **BEVAN et al.** *Nucl. Acids Res.*, 1980, vol. 12, 8711 [0140]
- **MOLONEY et al.** *Plant Cell Reports*, 1992, vol. 8, 238-242 [0142]
- **DEBLAERE et al.** *Nucl. Acids. Res.*, 1984, vol. 13, 4777-4788 [0143]
- **MURASHIGE ; SKOOG.** *Physiol. Plant.*, 1962, vol. 15, 473 [0143]
- **BELL et al.** *In Vitro Cell. Dev. Biol.-Plant.*, 1999, vol. 35 (6), 456-465 [0146]
- **MLYNAROVA et al.** *Plant Cell Report*, 1994, vol. 13, 282-285 [0146]